Method for producing hematopoietic progenitor cell and method for producing leukocyte
The use of a cell culture substrate with dot-shaped scaffolding and peptide-containing resins stabilizes the differentiation of hematopoietic progenitor cells and leukocytes from pluripotent stem cells, enhancing efficiency and yield.
Patent Information
- Application Number
- PCT/JP2024/019905
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-27
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
Conventional methods for differentiating hematopoietic progenitor cells and leukocytes from induced pluripotent stem cells are inefficient and unstable, with varying cell yields and marker expression rates depending on seeding conditions and stem cell type.
A method using a cell culture substrate with a base material and dot-shaped cell scaffolding material, where pluripotent stem cells are cultured to form clusters, and then induced to differentiate into hematopoietic progenitor cells and leukocytes, with specific conditions controlling cluster size and peptide-containing resin composition.
This method stabilizes the production of hematopoietic progenitor cells and leukocytes, increasing differentiation efficiency and reducing variations in cell number and marker expression, allowing for higher yields of functional cells.
Smart Images

Figure JP2024019905_05122024_PF_FP_ABST
Abstract
Description
Method for producing hematopoietic progenitor cells and method for producing leukocytes
[0001] The present invention relates to a method for producing hematopoietic progenitor cells. The present invention also relates to a method for producing leukocytes.
[0002] In recent years, attempts have been made to induce the differentiation of hematopoietic progenitor cells (hematopoietic stem cells) from induced pluripotent stem cells (iPS cells) and to induce the differentiation of leukocytes. iPS cells typically differentiate into mesodermal and hemogenic endothelial cells, and then into hematopoietic progenitor cells. Furthermore, hematopoietic progenitor cells differentiate into leukocytes.
[0003] For example, Non-Patent Document 1 below describes the induction of differentiation of iPS cells into monocytes, a type of white blood cell, using a plate whose entire bottom surface is coated with laminin.
[0004] Incidentally, Patent Document 1 listed below describes a surface layer having an area of 0.001 to 5 mm2 that has cell adhesive properties and cell proliferation properties. 2 Patent Document 1 discloses a method for inducing differentiation of pluripotent stem cells into ectodermal cells using a cell culture substrate having an island-like region (A) and a region (B) adjacent to region (A) that does not have cell adhesive or cell proliferation properties. However, the method described in Patent Document 1 is a method for inducing differentiation of pluripotent stem cells into ectodermal cells, and Patent Document 1 does not describe differentiating pluripotent stem cells into mesoderm, and therefore does not describe differentiating pluripotent stem cells into hematopoietic progenitor cells.
[0005] Furthermore, Patent Document 2 below describes a cell culture scaffold comprising a substrate and protrusions formed by patterning the substrate in dots or lines. The protrusions comprise a synthetic resin, and the synthetic resin comprises a polyvinyl alcohol derivative or a poly(meth)acrylic resin. An example of Patent Document 2 describes culturing iPS cells using a cell culture vessel comprising the cell culture scaffold. However, Patent Document 2 does not describe differentiation of iPS cells.
[0006] JP 2021-158960 A
[0007] High-Yield Human Induced Pluripotent Stem Cell-Derived Monocytes and Macrophages Are Functionally Comparable With Primary Cells (Front Cell Dev Biol. 2021 Apr 13;9:656867. doi: 10.3389 / fcell.2021.656867)
[0008] As described in Non-Patent Document 1, attempts have been made to differentiate iPS cells into blood cells such as hematopoietic progenitor cells and leukocytes using plates whose bottom surfaces are entirely coated with laminin. However, with conventional methods, the number of differentiated cells (hematopoietic progenitor cells or leukocytes) obtained and the expression rate of differentiation markers vary depending on the seeding conditions of the pluripotent stem cells and the type and state of the pluripotent stem cells, making it difficult to consistently obtain differentiated cells.
[0009] An object of the present invention is to provide a method for producing hematopoietic progenitor cells, which allows for stable production of hematopoietic progenitor cells from pluripotent stem cells and improves the efficiency of inducing differentiation of pluripotent stem cells into hematopoietic progenitor cells.Another object of the present invention is to provide a method for producing leukocytes, which allows for stable production of leukocytes from pluripotent stem cells and improves the efficiency of inducing differentiation of pluripotent stem cells into leukocytes.
[0010] The present specification discloses the following methods for producing hematopoietic progenitor cells and leukocytes.
[0011] Item 1. A method for producing hematopoietic progenitor cells, comprising: a cell cluster formation step of culturing pluripotent stem cells using a cell culture substrate comprising a substrate and a cell scaffold material arranged in a dot pattern on a first surface of the substrate, and forming cell clusters on the surface of the cell scaffold material; and a differentiation induction step of inducing differentiation of the obtained cell clusters into a cell population including hematopoietic progenitor cells.
[0012] Item 2. The method for producing hematopoietic progenitor cells according to Item 1, wherein the average equivalent circle diameter of the upper surface of the cell scaffold is 200 μm or more and 3000 μm or less.
[0013] Item 3. The method for producing hematopoietic progenitor cells according to Item 1 or 2, wherein the average distance between centers of gravity on the upper surface of the cell scaffold is 0.5 mm or more and 10 mm or less.
[0014] Item 4. The method for producing hematopoietic progenitor cells according to any one of Items 1 to 3, wherein the cell scaffold comprises a peptide-containing resin having a synthetic resin portion and a peptide portion.
[0015] Item 5. The method for producing hematopoietic progenitor cells according to Item 4, wherein the peptide-containing resin has a polyvinyl acetal resin portion and a peptide portion.
[0016] Item 6. The method for producing hematopoietic progenitor cells according to any one of Items 1 to 5, wherein the region of the first surface of the substrate where the cell scaffold is not disposed has a region that has been subjected to a low cell-adhesion treatment.
[0017] Item 7. The method for producing hematopoietic progenitor cells according to any one of Items 1 to 6, wherein the pluripotent stem cells are iPS cells.
[0018] Item 8. A method for producing leukocytes, comprising the step of inducing differentiation of a cell population containing hematopoietic progenitor cells obtained by the method for producing hematopoietic progenitor cells according to any one of Items 1 to 7 into a cell population containing monocytes, lymphocytes, or granulocytes.
[0019] Item 9. A method for producing leukocytes, comprising: a cell cluster formation step of culturing pluripotent stem cells using a cell culture substrate comprising a substrate and a cell scaffold material arranged in a dot pattern on a first surface of the substrate, and forming cell clusters on the surface of the cell scaffold material; and a differentiation induction step of inducing differentiation of the obtained cell clusters into a cell population comprising monocytes, lymphocytes, or granulocytes.
[0020] Item 10. The method for producing leukocytes according to Item 9, wherein the average equivalent circle diameter of the upper surface of the cell scaffold is 200 μm or more and 3000 μm or less.
[0021] Item 11. The method for producing leukocytes according to Item 9 or 10, wherein the average distance between centers of gravity on the upper surface of the cell scaffold is 0.5 mm or more and 10 mm or less.
[0022] Item 12. The method for producing leukocytes according to any one of Items 9 to 11, wherein the cell scaffold comprises a peptide-containing resin having a synthetic resin portion and a peptide portion.
[0023] Item 13. The method for producing leukocytes according to Item 12, wherein the peptide-containing resin has a polyvinyl acetal resin portion and a peptide portion.
[0024] Item 14. The method for producing leukocytes according to any one of Items 9 to 13, wherein the region of the first surface of the substrate where the cell scaffold is not disposed has a region that has been subjected to a low cell-adhesion treatment.
[0025] Item 15. The method for producing leukocytes according to any one of Items 9 to 14, wherein the pluripotent stem cells are iPS cells.
[0026] The method for producing hematopoietic progenitor cells according to the present invention comprises the steps of: culturing pluripotent stem cells using a cell culture substrate comprising a substrate and a cell scaffold material arranged in a dot pattern on a first surface of the substrate, and forming cell clusters on the surface of the cell scaffold material; and inducing differentiation of the obtained cell clusters into a cell population containing hematopoietic progenitor cells. Because the method for producing hematopoietic progenitor cells according to the present invention has the above-described configuration, it is possible to stably obtain hematopoietic progenitor cells from pluripotent stem cells and to increase the efficiency of inducing differentiation of pluripotent stem cells into hematopoietic progenitor cells.
[0027] The method for producing leukocytes according to the present invention comprises a cell cluster formation step of culturing pluripotent stem cells using a cell culture substrate comprising a substrate and a cell scaffold material arranged in a dot pattern on a first surface of the substrate, and forming cell clusters on the surface of the cell scaffold material, and a differentiation induction step of inducing differentiation of the obtained cell clusters into cell populations including monocytes, lymphocytes, or granulocytes. Because the method for producing leukocytes according to the present invention has the above-described configuration, it is possible to stably obtain leukocytes from pluripotent stem cells and to increase the efficiency of inducing differentiation of pluripotent stem cells into leukocytes.
[0028] 1(a) and 1(b) are a plan view and a cross-sectional view schematically illustrating an example of a cell culture substrate that can be used in the method for producing hematopoietic progenitor cells and the method for producing leukocytes. Fig. 2 shows an example of a flow chart for inducing differentiation of iPS cells into hematopoietic progenitor cells and then into leukocytes (monocytes, lymphocytes, or granulocytes).
[0029] The present invention will be described in detail below.
[0030] The method for producing hematopoietic progenitor cells according to the present invention comprises a cell mass formation step of culturing pluripotent stem cells using a cell culture substrate comprising a substrate and a cell scaffold material arranged in a dot pattern on a first surface of the substrate, and forming cell masses on the surface of the cell scaffold material; and a differentiation induction step of inducing differentiation of the obtained cell masses into a cell population including hematopoietic progenitor cells.
[0031] The method for producing hematopoietic progenitor cells according to the present invention has the above-described configuration, and therefore can stably obtain hematopoietic progenitor cells from pluripotent stem cells and can increase the efficiency of inducing differentiation from pluripotent stem cells to hematopoietic progenitor cells.
[0032] The present inventors have discovered that by using the above-described cell culture substrate and controlling the size of cell aggregates, it is possible to stably obtain hematopoietic progenitor cells from pluripotent stem cells and to increase the efficiency of inducing differentiation of pluripotent stem cells into hematopoietic progenitor cells. The method for producing hematopoietic progenitor cells according to the present invention allows for more stable production of hematopoietic progenitor cells from pluripotent stem cells than when a conventional cell culture substrate having a cell scaffold coated on the entire bottom surface is used. For example, the method for producing hematopoietic progenitor cells according to the present invention allows for more stable production of hematopoietic progenitor cells even under conditions of high seeding density of pluripotent stem cells than when a conventional cell culture substrate having a cell scaffold coated on the entire bottom surface is used.
[0033] The method for producing white blood cells according to the present invention comprises a cell cluster formation step of culturing pluripotent stem cells using a cell culture substrate comprising a substrate and a cell scaffold material arranged in a dot pattern on a first surface of the substrate, and forming cell clusters on the surface of the cell scaffold material; and a differentiation induction step of inducing differentiation of the obtained cell clusters into cell populations including monocytes, lymphocytes, or granulocytes.
[0034] The method for producing leukocytes according to the present invention has the above-mentioned configuration, and therefore can stably obtain leukocytes from pluripotent stem cells and can increase the efficiency of inducing differentiation of pluripotent stem cells into leukocytes.
[0035] The inventors have discovered that by using the above-mentioned cell culture substrate and controlling the size of cell aggregates, it is possible to stably obtain leukocytes from pluripotent stem cells and to increase the efficiency of inducing differentiation of pluripotent stem cells into leukocytes. The method for producing leukocytes according to the present invention allows for the stable production of leukocytes from pluripotent stem cells and increases the efficiency of inducing differentiation of pluripotent stem cells into leukocytes compared to when a conventional cell culture substrate whose entire bottom surface is coated with a cell scaffold is used. The method for producing leukocytes according to the present invention allows for a greater number of leukocytes to be obtained from a single pluripotent stem cell compared to when a conventional cell culture substrate whose entire bottom surface is coated with a cell scaffold is used.
[0036] The following is a possible reason why the above-described effects are exhibited by the methods for producing hematopoietic progenitor cells and leukocytes according to the present invention. Conventional methods using a cell culture substrate whose entire bottom surface is coated with a cell scaffold typically attempt to control the size of cell clusters and the distance between them by reducing the seeding density of pluripotent stem cells to prevent the formed cell clusters from adhering to each other. However, this method results in random cell cluster placement, resulting in some or many cell clusters adhering to each other, making it difficult to control the size of cell clusters and the distance between them. The present inventors have discovered that the reason conventional methods fail to consistently obtain differentiated cells (hematopoietic progenitor cells or leukocytes) or improve differentiation induction efficiency is due to large variations in the size of cell clusters and the distance between cell clusters. In contrast, the production method according to the present invention uses a cell culture substrate with a cell scaffold arranged in a dot pattern, thereby enabling control of the size of cell clusters, the number of cell clusters, and the distance between cell clusters. This facilitates uniform distribution of differentiation-inducing factors to cells. Furthermore, cytokines secreted from cell clusters become uniform, resulting in uniform promotion of differentiation induction among cell clusters (paracrine effect). This allows differentiated cells (hematopoietic progenitor cells or leukocytes) to be stably obtained from pluripotent stem cells, and the efficiency of inducing differentiation from pluripotent stem cells to differentiated cells (hematopoietic progenitor cells or leukocytes) to be increased. The production method of the present invention can, for example, effectively reduce variations in the number of differentiated cells (hematopoietic progenitor cells or leukocytes) obtained and the expression rate of differentiation markers, allowing differentiated cells to be stably obtained. Furthermore, the number of differentiated cells (hematopoietic progenitor cells or leukocytes) obtained from a single pluripotent stem cell can be increased, thereby increasing the efficiency of differentiation induction. However, the above is merely an estimate, and the reason why the production method of the present invention can exhibit the above effects is not limited to this.
[0037] First, a cell culture substrate that can be used in the method for producing hematopoietic progenitor cells and the method for producing leukocytes according to the present invention will be described.
[0038] [Cell Culture Substrate] The cell culture substrate comprises a substrate and a cell scaffold arranged in a dot pattern on a first surface of the substrate. The first surface of the substrate has an area where the cell scaffold is arranged and an area where the cell scaffold is not arranged.
[0039] Examples of cell culture substrates will be described below with reference to the drawings.
[0040] 1(a) and 1(b) are a plan view and a cross-sectional view, respectively, schematically illustrating an example of a cell culture substrate that can be used in the method for producing hematopoietic progenitor cells and the method for producing leukocytes, where Fig. 1(a) is a plan view and Fig. 1(b) is a cross-sectional view taken along line II of Fig. 1(a).
[0041] The cell culture substrate 1 shown in Figure 1 comprises a substrate 2 and a cell scaffold 3. The cell scaffold 3 is arranged in a dot pattern on the first surface 2a of the substrate 2. The first surface 2a of the substrate 2 and the cell scaffold 3 are in direct contact with each other. The cell scaffold 3 is arranged periodically and at equal intervals on the first surface 2a of the substrate 2. The cell scaffold 3 has an upper surface 3a. The upper surface 3a of the cell scaffold 3 is the surface of the cell scaffold 3 opposite to the first surface 2a of the substrate 2.
[0042] In the cell culture substrate 1, the outer shape of the upper surface 3a of the cell scaffold 3 is circular. In FIG. 1( a), the symbol D is the diameter of the upper surface 3a of the cell scaffold 3. In the cell culture substrate 1, the outer shape of the upper surface 3a of the cell scaffold 3 is circular, so the diameter D of the upper surface 3a of the cell scaffold 3 corresponds to the equivalent circle diameter of the upper surface 3a of the cell scaffold 3. In FIG. 1( a), the symbol L is the distance between the centers of gravity of the upper surfaces 3a of the cell scaffold 3. In the cell culture substrate 1, the outer shape of the upper surface 3a of the cell scaffold 3 is circular, so the distance L between the centers of gravity of the upper surfaces 3a of the cell scaffold 3 is the distance between the centers of the circles that form the outer shape of the upper surfaces 3a of the cell scaffold 3. In FIG. 1( b), the symbol H is the height of the cell scaffold 3. The height H of the cell scaffold 3 is the distance from the first surface 2a of the substrate 2 to the upper surface 3a of the cell scaffold 3.
[0043] (Substrate) The cell culture substrate includes a substrate (cell culture substrate body). The material, size, and shape of the substrate are not particularly limited. Conventionally known substrates can be used as the substrate.
[0044] Examples of the material for the substrate include synthetic resin, metal, glass, etc. Examples of the synthetic resin include polystyrene, polyethylene, polypropylene, polyethersulfone, polycarbonate, polyester, polyisoprene, cycloolefin polymer, polyimide, polyamide, polyamideimide, (meth)acrylic resin, epoxy resin, and silicone.
[0045] The substrate may be in the form of a plate, a film, a porous membrane, a bag, etc. The substrate may also be in the form of a container.
[0046] The substrate is preferably a container. The cell culture substrate is preferably a cell culture vessel. The cell culture substrate is preferably a cell culture vessel comprising a container (cell culture vessel body) and a cell scaffold material arranged in a dot pattern on a first surface of the container. The shape and size of the container (cell culture vessel body) are not particularly limited. Examples of the container (cell culture vessel body) include 2- to 384-well plates, single-layer flasks, multi-layer flasks, multi-sided flasks, dishes, roller bottles, bags, insert cups, and microchannel chips. The first surface of the substrate is preferably the bottom surface of the vessel.
[0047] (Cell scaffold material) The cell culture substrate comprises a cell scaffold material. The cell scaffold material is arranged in a dot pattern on the first surface of the substrate. The cell scaffold material has an upper surface. The upper surface of the cell scaffold material is the surface of the cell scaffold material opposite to the first surface side of the substrate.
[0048] The outer shape of the upper surface of the cell scaffold is not particularly limited, and may be circular, elliptical, polygonal, or any other shape.
[0049] The number of the cell scaffold materials (the number of dots) arranged on the first surface of the substrate can be changed as appropriate depending on the type, shape, size, etc. of the substrate. For example, the number of the cell scaffold materials (the number of dots) arranged on the first surface of the substrate is set to 1 cm per square meter of the area of the first surface of the substrate. 2 The number may be 1 or more, 3 or more, 5 or more, 7 or more, 150 or less, 120 or less, 90 or less, or 60 or less per molecule.
[0050] The cell scaffold materials may be arranged at equal intervals on the first surface of the substrate, or may not be arranged at equal intervals. The cell culture substrate may have a region where the cell scaffold materials are arranged at equal intervals on the first surface of the substrate and a region where they are not arranged at equal intervals. The cell scaffold materials may be arranged periodically on the first surface of the substrate, or may not be arranged periodically. The cell culture substrate may have a region where the cell scaffold materials are arranged periodically on the first surface of the substrate and a region where they are not arranged periodically.
[0051] The average aspect ratio of the upper surface of the cell scaffold is preferably 6 or less, more preferably 5 or less, even more preferably 4 or less, even more preferably 3 or less, even more preferably 2 or less, particularly preferably 1.5 or less, and most preferably 1.25 or less. When the average aspect ratio is equal to or less than the upper limit, cell aggregates can be formed more effectively. The average aspect ratio of the upper surface of the cell scaffold may be 1 or more, or may exceed 1.
[0052] The aspect ratio is the ratio of the major axis of the upper surface of the cell scaffold to the minor axis of the upper surface of the cell scaffold (major axis / minor axis). The aspect ratio can be calculated, for example, by photographing the surface of the cell culture substrate with a microscope and analyzing the microscopic photograph using commercially available image analysis software. The average aspect ratio is determined by averaging the aspect ratios of the upper surfaces of multiple cell scaffolds. The average aspect ratio is preferably determined by averaging the aspect ratios of the upper surfaces of 10 or more cell scaffolds arbitrarily selected from the entire first surface of the substrate. When fewer than 10 cell scaffolds are present on the first surface of the substrate, the average aspect ratio is preferably determined by averaging the aspect ratios of the upper surfaces of all the cell scaffolds.
[0053] The average circle-equivalent diameter of the upper surface of the cell scaffold is preferably 200 μm or more, more preferably 300 μm or more, even more preferably 350 μm or more, even more preferably 400 μm or more, particularly preferably 500 μm or more, preferably 3000 μm or less, more preferably 2500 μm or less, even more preferably 2000 μm or less, even more preferably 1500 μm or less, and particularly preferably 1000 μm or less. When the average circle-equivalent diameter is equal to or greater than the lower limit and equal to or less than the upper limit, it becomes easier to control the size of the cell aggregate within a suitable range, and the effects of the present invention can be exerted even more effectively.
[0054] The circle-equivalent diameter refers to the diameter of a circle having the same area as the area of the upper surface of the cell scaffold. The circle-equivalent diameter can be calculated using the following formula. The circle-equivalent diameter can be calculated, for example, by photographing the surface of the cell culture substrate with a microscope and analyzing the micrograph using commercially available image analysis software. The average circle-equivalent diameter is determined by averaging the circle-equivalent diameters of the upper surfaces of multiple cell scaffolds. The average circle-equivalent diameter is preferably determined by averaging the circle-equivalent diameters of the upper surfaces of 10 or more cell scaffolds arbitrarily selected from the entire first surface of the substrate. When fewer than 10 cell scaffolds are present on the first surface of the substrate, the average circle-equivalent diameter is preferably determined by averaging the circle-equivalent diameters of the upper surfaces of all the cell scaffolds.
[0055]
[0056] D: Equivalent circle diameter of the upper surface of the cell scaffold S: Area of the upper surface of the cell scaffold
[0057] The average value of the distance between the centers of gravity on the upper surface of the cell scaffold is preferably 0.5 mm or more, more preferably 0.7 mm or more, even more preferably 1 mm or more, even more preferably 1.5 mm or more, particularly preferably 2 mm or more, preferably 10 mm or less, more preferably 9 mm or less, even more preferably 8 mm or less, even more preferably 7 mm or less, even more preferably 6 mm or less, and particularly preferably 5 mm or less. When the average value of the distance between the centers of gravity is equal to or greater than the above lower limit and equal to or less than the above upper limit, it becomes easier to control the distance between cell aggregates within a suitable range, and the effects of the present invention can be exerted even more effectively.
[0058] The distance between centers of gravity is the distance from the center of gravity of the upper surface of the cell scaffold to the center of gravity of the upper surface of the cell scaffold that is closest to the center of gravity of the upper surface of the cell scaffold (the distance between a certain center of gravity and another center of gravity that is closest to the certain center of gravity). The distance between centers of gravity can be calculated, for example, by photographing the surface of the cell culture substrate with a microscope and analyzing the microscopic photograph using commercially available image analysis software. The average distance between centers of gravity is determined by averaging the distance between centers of gravity of the upper surfaces of multiple cell scaffolds. The average distance between centers of gravity is preferably determined by averaging the distance between centers of gravity of the upper surfaces of 10 or more cell scaffolds arbitrarily selected from the entire first surface of the substrate. When fewer than 10 cell scaffolds are present on the first surface of the substrate, the average distance between centers of gravity of the upper surfaces of all the cell scaffolds is preferably determined.
[0059] The average height of the cell scaffold may be 1 nm or more, 5 nm or more, 10 nm or more, 15 nm or more, 20 nm or more, 10 μm or less, 5 μm or less, 2 μm or less, or 1 μm or less. When the average height of the cell scaffold is equal to or greater than the lower limit, the adhesion of cells to the cell scaffold can be improved, and cell proliferation can be enhanced. When the average height of the cell scaffold is equal to or less than the upper limit, the manufacturing cost of the cell culture substrate can be kept low.
[0060] The height of the cell scaffold is the distance from the first surface of the substrate to the upper surface of the cell scaffold. The height of the cell scaffold is preferably the distance from the first surface of the substrate to the center of gravity of the upper surface of the cell scaffold. The average height is determined by averaging the heights of multiple cell scaffolds. The average height is preferably determined by averaging the heights of 10 or more cell scaffolds arbitrarily selected from the entire first surface of the substrate. When there are fewer than 10 cell scaffolds on the first surface of the substrate, the average height is preferably determined by averaging the heights of all the cell scaffolds.
[0061] The microscope used to measure the aspect ratio, circle equivalent diameter, and center-of-gravity distance of the upper surface of the cell scaffold material, as well as the height of the cell scaffold material, may be, for example, the "BZ-X800" manufactured by Keyence Corporation, and the analytical application may be, for example, the "BZ-H4M / Measurement Application" manufactured by Keyence Corporation.
[0062] Components contained in the cell scaffold include cell adhesive proteins, synthetic resins, etc. The above components may be used alone or in combination of two or more.
[0063] Examples of the cell adhesive protein include laminin, vitronectin, and collagen. The component contained in the cell scaffold may be a component containing a cell adhesive protein such as Matrigel. Examples of the Matrigel include Matrigel derived from mouse sarcoma.
[0064] As described below, the synthetic resin may include a synthetic resin having a synthetic resin portion and a peptide portion (a synthetic resin to which a peptide is bonded). The synthetic resin may also include a synthetic resin not having a peptide portion (a synthetic resin to which a peptide is not bonded). Examples of the synthetic resin include polyvinyl alcohol derivatives, peptide-containing polyvinyl alcohol derivatives having a polyvinyl alcohol derivative portion and a peptide portion, (meth)acrylic copolymers, and peptide-containing (meth)acrylic copolymers having a poly(meth)acrylic acid ester portion and a peptide portion. Examples of the polyvinyl alcohol derivatives include polyvinyl acetal resins.
[0065] Hereinafter, in this specification, the above-mentioned "synthetic resin having a synthetic resin portion and a peptide portion" may be referred to as a "peptide-containing resin."
[0066] The cell scaffold preferably contains a cell adhesive protein or a synthetic resin, more preferably contains laminin, vitronectin, or a peptide-containing resin, and even more preferably contains a peptide-containing resin, which can more effectively exert the effects of the present invention.
[0067] <Peptide-Containing Resin> From the viewpoint of more effectively exerting the effects of the present invention and increasing the production efficiency of a cell culture substrate, the cell scaffold preferably contains a peptide-containing resin having a synthetic resin portion and a peptide portion. The peptide-containing resin is a synthetic resin to which a peptide is bound. The peptide-containing resin has a synthetic resin portion and a peptide portion. Only one type of peptide-containing resin may be used, or two or more types may be used in combination.
[0068] The synthetic resin portion preferably has a polyvinyl alcohol derivative portion or a poly(meth)acrylic acid ester portion, more preferably a polyvinyl alcohol derivative portion or a poly(meth)acrylic acid ester portion. The peptide-containing resin preferably has a polyvinyl alcohol derivative portion or a poly(meth)acrylic acid ester portion and a peptide portion. In this case, the effects of the present invention can be more effectively exhibited. The peptide-containing resin may have both a polyvinyl alcohol derivative portion and a poly(meth)acrylic acid ester portion.
[0069] In the peptide-containing resin having the polyvinyl alcohol derivative portion, the polyvinyl alcohol derivative portion and the peptide portion are preferably bonded via a linker portion. Therefore, the peptide-containing resin having the polyvinyl alcohol derivative portion preferably has a polyvinyl alcohol derivative portion, a peptide portion, and a linker portion.
[0070] In the peptide-containing resin having the poly(meth)acrylic acid ester moiety, the poly(meth)acrylic acid ester moiety and the peptide moiety may be bonded via a linker moiety or may be bonded directly without a linker moiety. The peptide-containing resin having the poly(meth)acrylic acid ester moiety may have a poly(meth)acrylic acid ester moiety, a peptide moiety, and a linker moiety.
[0071] In this specification, "(meth)acrylic" means one or both of "acrylic" and "methacrylic", and "(meth)acrylate" means one or both of "acrylate" and "methacrylate".
[0072] <<Polyvinyl alcohol derivative moiety>> The polyvinyl alcohol derivative moiety (polyvinyl alcohol derivative skeleton) is a structural moiety derived from a polyvinyl alcohol derivative. The polyvinyl alcohol derivative is a compound derived from polyvinyl alcohol.
[0073] The peptide-containing resin is preferably a peptide-containing polyvinyl alcohol derivative having a polyvinyl alcohol derivative portion and a peptide portion. The cell scaffold preferably contains a peptide-containing polyvinyl alcohol derivative having a polyvinyl alcohol derivative portion and a peptide portion. By using the peptide-containing polyvinyl alcohol derivative, the effects of the present invention can be more effectively exerted and cell proliferation can be further enhanced.
[0074] From the viewpoint of even more effectively exerting the effects of the present invention and even more effectively enhancing cell proliferation, the polyvinyl alcohol derivative is preferably a polyvinyl acetal resin, and the polyvinyl alcohol derivative portion is preferably a polyvinyl acetal resin portion. That is, the peptide-containing resin preferably has a polyvinyl acetal resin portion and a peptide portion. The cell scaffold preferably contains a peptide-containing polyvinyl acetal resin having a polyvinyl acetal resin portion and a peptide portion. The polyvinyl alcohol derivative and the polyvinyl acetal resin may each be used alone or in combination of two or more types.
[0075] The polyvinyl alcohol derivative portion and the polyvinyl acetal resin portion preferably have an acetal group, a hydroxyl group, and an acetyl group in their side chains. However, the polyvinyl alcohol derivative portion and the polyvinyl acetal resin portion may not have an acetyl group, for example. For example, by bonding all of the acetyl groups in the polyvinyl acetal resin portion to a linker, the polyvinyl alcohol derivative portion and the polyvinyl acetal resin portion may not have an acetyl group.
[0076] The polyvinyl acetal resin can be synthesized by acetalizing polyvinyl alcohol with an aldehyde.
[0077] The aldehyde used for acetalization of polyvinyl alcohol is not particularly limited. Examples of the aldehyde include aldehydes having 1 to 10 carbon atoms. The aldehyde may or may not have a chain aliphatic group, a cyclic aliphatic group, or an aromatic group. The aldehyde may be a chain aldehyde or a cyclic aldehyde. Only one type of the aldehyde may be used, or two or more types may be used in combination.
[0078] From the viewpoint of further enhancing the adhesiveness between the cell scaffold and cells and from the viewpoint of more effectively exerting the effects of the present invention, the aldehyde is preferably formaldehyde, acetaldehyde, propionaldehyde, butyraldehyde, or pentanal, and more preferably butyraldehyde. Therefore, the polyvinyl acetal resin is more preferably a polyvinyl butyral resin. From the viewpoint of further enhancing the adhesiveness between the cell scaffold and cells and from the viewpoint of more effectively exerting the effects of the present invention, the polyvinyl acetal resin portion is preferably a polyvinyl butyral resin portion. The peptide-containing resin preferably has a polyvinyl butyral resin portion and a peptide portion. The cell scaffold preferably includes a peptide-containing polyvinyl butyral resin having a polyvinyl butyral resin portion and a peptide portion.
[0079] In the peptide-containing polyvinyl acetal resin, the degree of acetalization of the polyvinyl acetal resin portion (the degree of butyralization in the case of a polyvinyl butyral resin portion) is preferably 40 mol% or more, more preferably 50 mol% or more, and preferably 90 mol% or less, more preferably 85 mol% or less. If the acetalization degree is above the lower limit, the peptide-containing polyvinyl acetal resin is less likely to swell in the culture medium. If the acetalization degree is below the upper limit, the solubility in solvents can be improved.
[0080] In the peptide-containing polyvinyl acetal resin, the hydroxyl group content (hydroxyl group amount) of the polyvinyl acetal resin portion is preferably 15 mol % or more, more preferably 20 mol % or more, and preferably 45 mol % or less, more preferably 30 mol % or less, and even more preferably 25 mol % or less.
[0081] In the peptide-containing polyvinyl acetal resin, the degree of acetylation (amount of acetyl groups) of the polyvinyl acetal resin portion is preferably 1 mol % or more, more preferably 2 mol % or more, and preferably 5 mol % or less, more preferably 4 mol % or less. When the degree of acetylation is equal to or greater than the above lower limit and equal to or less than the above upper limit, the reaction efficiency between the polyvinyl acetal resin and the linker can be increased.
[0082] The degree of acetalization, the degree of acetylation, and the amount of hydroxyl groups in the polyvinyl acetal resin part are 1 The degree of acetalization, the degree of acetylation, and the amount of hydroxyl groups in the polyvinyl acetal resin portion are usually expressed as mole percent relative to the total amount (100 mole percent) of the substance of each structural unit constituting the peptide-containing polyvinyl acetal resin.
[0083] <<Poly(meth)acrylic acid ester moiety>> The poly(meth)acrylic acid ester moiety (poly(meth)acrylic acid ester skeleton) is a structural moiety derived from a poly(meth)acrylic acid ester.
[0084] The peptide-containing resin preferably has a poly(meth)acrylic acid ester moiety, and more preferably is a peptide-containing (meth)acrylic copolymer having a poly(meth)acrylic acid ester moiety and a peptide moiety. The cell scaffold preferably contains a peptide-containing (meth)acrylic copolymer having a poly(meth)acrylic acid ester moiety and a peptide moiety. By using the peptide-containing (meth)acrylic copolymer, the effects of the present invention can be more effectively exerted and cell proliferation can be further enhanced.
[0085] The poly(meth)acrylic acid ester moiety has a skeleton derived from a (meth)acrylic acid ester. The poly(meth)acrylic acid ester is obtained by polymerizing a (meth)acrylic acid ester. The poly(meth)acrylic acid ester may be used alone or in combination of two or more.
[0086] Examples of the (meth)acrylic acid ester include (meth)acrylic acid alkyl esters, (meth)acrylic acid cyclic alkyl esters, (meth)acrylic acid aryl esters, (meth)acrylic acid polyethylene glycols, (meth)acrylic acid phosphorylcholine, etc. The (meth)acrylic acid esters may be used alone or in combination of two or more.
[0087] Examples of the (meth)acrylic acid alkyl ester include methyl (meth)acrylate, ethyl (meth)acrylate, n-propyl (meth)acrylate, isopropyl (meth)acrylate, n-butyl (meth)acrylate, isobutyl (meth)acrylate, t-butyl (meth)acrylate, n-octyl (meth)acrylate, isooctyl (meth)acrylate, 2-ethylhexyl (meth)acrylate, nonyl (meth)acrylate, isononyl (meth)acrylate, decyl (meth)acrylate, isodecyl (meth)acrylate, lauryl (meth)acrylate, stearyl (meth)acrylate, and isotetradecyl (meth)acrylate.
[0088] The (meth)acrylic acid alkyl ester may be substituted with a substituent such as an alkoxy group having 1 to 3 carbon atoms and a tetrahydrofurfuryl group. Examples of such (meth)acrylic acid alkyl esters include methoxyethyl acrylate and tetrahydrofurfuryl acrylate.
[0089] Examples of the (meth)acrylic acid cyclic alkyl ester include cyclohexyl (meth)acrylate and isobornyl (meth)acrylate.
[0090] Examples of the (meth)acrylic acid aryl ester include phenyl (meth)acrylate and benzyl (meth)acrylate.
[0091] Examples of the polyethylene glycol (meth)acrylates include methoxy-polyethylene glycol (meth)acrylate, ethoxy-polyethylene glycol (meth)acrylate, hydroxy-polyethylene glycol (meth)acrylate, methoxy-diethylene glycol (meth)acrylate, ethoxy-diethylene glycol (meth)acrylate, hydroxy-diethylene glycol (meth)acrylate, methoxy-triethylene glycol (meth)acrylate, ethoxy-triethylene glycol (meth)acrylate, and hydroxy-triethylene glycol (meth)acrylate.
[0092] Examples of the (meth)acrylate phosphorylcholine include 2-(meth)acryloyloxyethyl phosphorylcholine.
[0093] The peptide-containing resin having the poly(meth)acrylic acid ester moiety may have a skeleton derived from a monomer other than a (meth)acrylic acid ester.
[0094] Examples of the monomer other than the (meth)acrylic acid ester include (meth)acrylamides, vinyl compounds, etc. The monomer other than the (meth)acrylic acid ester may be used alone or in combination of two or more thereof.
[0095] Examples of the (meth)acrylamides include (meth)acrylamide, N-isopropyl(meth)acrylamide, N-tert-butyl(meth)acrylamide, N,N'-dimethyl(meth)acrylamide, (3-(meth)acrylamidopropyl)trimethylammonium chloride, 4-(meth)acryloylmorpholine, 3-(meth)acryloyl-2-oxazolidinone, N-[3-(dimethylamino)propyl](meth)acrylamide, N-(2-hydroxyethyl)(meth)acrylamide, N-methylol(meth)acrylamide, and 6-(meth)acrylamidohexanoic acid.
[0096] Examples of the vinyl compound include ethylene, allylamine, vinylpyrrolidone, maleic anhydride, maleimide, itaconic acid, (meth)acrylic acid, and vinylamine.
[0097] <<Peptide portion>> The peptide portion is a structural portion derived from a peptide. The peptide portion has an amino acid sequence. The peptide constituting the peptide portion may be an oligopeptide or a polypeptide. Only one type of peptide may be used, or two or more types may be used in combination.
[0098] The number of amino acid residues in the peptide portion is preferably 3 or more, more preferably 4 or more, even more preferably 5 or more, and preferably 10 or less, more preferably 8 or less, and even more preferably 6 or less. When the number of amino acid residues is equal to or greater than the above-mentioned lower limit and equal to or less than the above-mentioned upper limit, the adhesiveness between the cell scaffold and the cells after seeding can be further improved, and the cell proliferation rate can be further increased. However, the number of amino acid residues in the peptide portion may be more than 10 or more than 15.
[0099] The peptide portion preferably has a cell-adhesive amino acid sequence. The cell-adhesive amino acid sequence refers to an amino acid sequence whose cell-adhesive activity has been confirmed by phage display, Sepharose bead, or plate coating. The phage display method can be, for example, the method described in "The Journal of Cell Biology, Volume 130, Number 5, September 1995, pp. 1189-1196." The Sepharose bead method can be, for example, the method described in "Protein, Nucleic Acid, Enzyme, Vol. 45, No. 15 (2000) 2477." The plate coating method can be, for example, the method described in "Protein, Nucleic Acid, Enzyme, Vol. 45, No. 15 (2000) 2477."
[0100] Examples of the cell adhesive amino acid sequence include the RGD sequence (Arg-Gly-Asp), the YIGSR sequence (Tyr-Ile-Gly-Ser-Arg), the PDSGR sequence (Pro-Asp-Ser-Gly-Arg), the HAV sequence (His-Ala-Val), the ADT sequence (Ala-Asp-Thr), and the QAV sequence (Gln-Ala-Val). ), LDV sequence (Leu-Asp-Val), IDS sequence (Ile-Asp-Ser), REDV sequence (Arg-Glu-Asp-Val), IDAPS sequence (Ile-Asp-Ala-Pro-Ser), KQAGDV sequence (Lys-Gln-Ala-Gly-Asp-Val), and TDE sequence (Thr-Asp-Glu). Examples of the cell-adhesive amino acid sequence include those described in "Pathophysiology, Vol. 9, No. 7, pp. 527-535, 1990" and "Osaka Prefectural Maternal and Child Medical Center Journal, Vol. 8, No. 1, pp. 58-66, 1992." The peptide portion may have only one or more of the cell-adhesive amino acid sequences.
[0101] The peptide moiety preferably has at least one of the above-mentioned cell-adhesive amino acid sequences, more preferably has at least an RGD sequence, a YIGSR sequence, or a PDSGR sequence, even more preferably has an RGD sequence, and particularly preferably has at least an RGD sequence represented by the following formula (1): In this case, the adhesiveness between the cell scaffold and the cells after seeding can be further increased, and the cell proliferation rate can be further increased.
[0102] Arg-Gly-Asp-X...Formula (1)
[0103] In the above formula (1), X represents Gly, Ala, Val, Ser, Thr, Phe, Met, Pro, or Asn.
[0104] The peptide portion may be linear or may have a cyclic peptide backbone. The cyclic peptide backbone is a cyclic backbone composed of a plurality of amino acids. From the viewpoint of more effectively exerting the effects of the present invention, the cyclic peptide backbone is preferably composed of four or more amino acids, more preferably five or more amino acids, and preferably ten or less amino acids.
[0105] In the peptide-containing resin, the content of the peptide moiety is preferably 0.05 mol% or more, more preferably 0.1 mol% or more, even more preferably 0.15 mol% or more, particularly preferably 0.2 mol% or more, preferably 25 mol% or less, more preferably 20 mol% or less, even more preferably 15 mol% or less, and particularly preferably 10 mol% or less. When the content of the peptide moiety is equal to or greater than the lower limit, the adhesiveness between the cell scaffold and the cells after seeding can be further improved, and the cell proliferation rate can be further increased. Furthermore, when the content of the peptide moiety is equal to or less than the upper limit, production costs can be reduced.
[0106] The content (mol %) of the peptide moiety is the amount of the peptide moiety relative to the total amount of each structural unit constituting the peptide-containing resin.
[0107] The content of the peptide moiety can be measured, for example, by NMR (nuclear magnetic resonance).
[0108] <<Linker Part>> The linker part is a structural moiety derived from a linker. The linker part is usually located between the polyvinyl alcohol derivative part or the poly(meth)acrylic acid ester part and the peptide part. The polyvinyl alcohol derivative part or the poly(meth)acrylic acid ester part and the peptide part are bonded via the linker part. The linker part is formed by a linker (crosslinking agent). Only one type of linker may be used, or two or more types may be used in combination.
[0109] The linker is preferably a compound having a functional group capable of binding to the peptide, and more preferably a compound having a functional group capable of condensing with a carboxyl group or amino group of the peptide.
[0110] Examples of the functional group capable of condensing with the carboxyl group or amino group of the peptide include a carboxyl group, a thiol group, an amino group, a hydroxyl group, and a cyano group.
[0111] From the viewpoint of favorable reaction with the peptide, the linker is preferably a compound having a carboxyl group or an amino group, and more preferably a compound having a carboxyl group.
[0112] When a peptide-containing resin having a polyvinyl alcohol derivative portion is obtained, examples of the linker having a carboxyl group include (meth)acrylic acid and a carboxyl group-containing acrylamide, etc. By using a carboxylic acid (carboxylic acid monomer) having a polymerizable unsaturated group as the linker having a carboxyl group, the carboxylic acid monomer can be polymerized by graft polymerization when the linker is introduced, thereby increasing the number of carboxyl groups that can react with the peptide.
[0113] From the viewpoint of effectively binding the polyvinyl alcohol derivative and the peptide, the linker is preferably (meth)acrylic acid, and more preferably acrylic acid.
[0114] When obtaining a peptide-containing resin having a poly(meth)acrylic acid ester moiety, the linker preferably has a functional group capable of bonding to a (meth)acrylic acid ester. Examples of the functional group capable of bonding to a (meth)acrylic acid ester include a vinyl group, a (meth)acryloyl group, and an allyl group. The linker more preferably has a (meth)acryloyl group as the functional group capable of bonding to the (meth)acrylic acid ester, and is preferably a compound having a carboxyl group or an amino group and a (meth)acryloyl group.
[0115] Examples of the linker for obtaining a peptide-containing resin having a poly(meth)acrylic acid ester moiety include (meth)acrylic acid, itaconic acid, and acrylamide.
[0116] From the viewpoint of effectively bonding the poly(meth)acrylic acid ester and the peptide, the linker is preferably (meth)acrylic acid or itaconic acid, and more preferably (meth)acrylic acid.
[0117] <Other Details of Cell Scaffold> The number-average molecular weight of the peptide-containing resin is preferably 10,000 or more, more preferably 50,000 or more, even more preferably 100,000 or more, preferably 5,000,000 or less, more preferably 2,500,000 or less, and even more preferably 1,000,000 or less. If the number-average molecular weight is above the lower limit, the cell scaffold is less likely to be eluted into the liquid medium during cell culture, and the cell scaffold is less likely to peel off from the substrate during cell culture. If the number-average molecular weight is below the upper limit, solubility in alcohol solvents can be increased.
[0118] The number-average molecular weight of the peptide-containing resin can be measured, for example, by the following method: The peptide-containing resin is dissolved in tetrahydrofuran (THF) to prepare a 0.2 wt% solution of the peptide-containing resin. The molecular weight is then evaluated using a gel permeation chromatography (GPC) measuring device (APC system, manufactured by Waters) under the following measurement conditions:
[0119] Column: HSPgel HR MB-M 6.0 x 150 mm Flow rate: 0.5 mL / min Column temperature: 40°C Injection volume: 10 μL Detector: RI, PDA Standard sample: polystyrene
[0120] The cell scaffold may contain a synthetic resin without a peptide moiety (a synthetic resin to which no peptide is bound) and a peptide-containing resin. The cell scaffold may contain a synthetic resin with the polyvinyl alcohol derivative moiety or poly(meth)acrylic acid ester moiety but without a peptide moiety, and a peptide-containing resin. The cell scaffold may contain other components, such as a resin without both the polyvinyl alcohol derivative moiety and the poly(meth)acrylic acid ester moiety. Examples of the other components include polyolefin resins, polyether resins, polyesters, epoxy resins, polyamide resins, polyimide resins, polyurethane resins, polycarbonate resins, cellulose, and polypeptides. Only one type of the other component may be used, or two or more types may be used in combination.
[0121] The cell scaffold preferably contains the peptide-containing resin and does not contain or contains synthetic resin to which no peptide is bound.
[0122] The cell scaffold preferably has a layer containing the peptide-containing resin. The cell scaffold may have only a layer containing the peptide-containing resin, or may have a layer containing the peptide-containing resin and a layer containing a synthetic resin to which no peptide is bound. From the viewpoint of more effectively exerting the effects of the present invention and further enhancing cell proliferation, the first surface of the layer containing the peptide-containing resin is preferably the upper surface of the cell scaffold. The peptide-containing resin is preferably present at least on the upper surface of the cell scaffold.
[0123] The content of the peptide-containing resin in 100% by weight of the cell scaffold is preferably 90% by weight or more, more preferably 95% by weight or more, even more preferably 97.5% by weight or more, particularly preferably 99% by weight or more, and most preferably 100% by weight (total amount). When the content of the peptide-containing resin is equal to or greater than the lower limit, the effects of the present invention can be more effectively exerted. The content of the peptide-containing resin in 100% by weight of the cell scaffold may be 100% by weight or less, or may be less than 100% by weight.
[0124] The total content of the peptide-containing resin and the synthetic resin to which no peptide is bound, based on 100% by weight of the cell scaffold, is preferably 90% by weight or more, more preferably 95% by weight or more, even more preferably 97.5% by weight or more, particularly preferably 99% by weight or more, and most preferably 100% by weight (total amount). When this total is equal to or greater than the lower limit, the effects of the present invention can be more effectively exerted. The total content of the peptide-containing resin and the synthetic resin to which no peptide is bound, based on 100% by weight of the cell scaffold, may be 100% by weight or less, or may be less than 100% by weight.
[0125] The cell scaffold preferably has a layer containing the cell adhesive protein. The cell scaffold may have only a layer containing the cell adhesive protein, or may have a layer containing the cell adhesive protein and a layer not containing the cell adhesive protein. From the viewpoint of more effectively exerting the effects of the present invention and further enhancing cell proliferation, the first surface of the layer containing the cell adhesive protein is preferably the upper surface of the cell scaffold. The cell adhesive protein is preferably present at least on the upper surface of the cell scaffold.
[0126] The content of the cell adhesive protein in 100% by weight of the cell scaffold is preferably 90% by weight or more, more preferably 95% by weight or more, even more preferably 97.5% by weight or more, particularly preferably 99% by weight or more, and most preferably 100% by weight (total amount). When the content of the cell adhesive protein is equal to or greater than the lower limit, the effects of the present invention can be more effectively exerted. The content of the cell adhesive protein in 100% by weight of the cell scaffold may be 100% by weight or less, or may be less than 100% by weight.
[0127] (Other Details of the Cell Culture Substrate) In the cell culture substrate, a cell scaffold is arranged in a dot pattern on the first surface of the substrate. In the cell culture substrate, it is preferable that the region of the first surface of the substrate where the cell scaffold is not arranged has a region that has been subjected to a low cell adhesion treatment. In this case, the efficiency of inducing differentiation of pluripotent stem cells into hematopoietic progenitor cells can be further improved. While the reason for this is unclear, the following possibilities are considered: The extension of endothelial cells into the low cell adhesion treated region may be effectively suppressed, and the endothelial cells may be localized on the cell scaffold, thereby promoting differentiation induction into hematopoietic progenitor cells; The adsorption of supplements in the liquid medium to the substrate may be effectively suppressed, thereby promoting differentiation induction into hematopoietic progenitor cells. However, the above is speculation, and the reason why the substrate having the low cell adhesion treated region can further improve differentiation induction efficiency is not limited to this.
[0128] Examples of the low cell adhesion treatment include coating treatment with a fluorine-based polymer, an amphoteric polymer, an MPC polymer, a hydrogel, etc. Examples of commercially available substrates that have been subjected to such low cell adhesion treatment include low-adhesion treated containers and ultra-low-adhesion treated containers.
[0129] From the viewpoint of further increasing the efficiency of differentiation induction, the region subjected to the low cell adhesion treatment is preferably a region coated with an MPC polymer or a hydrogel.
[0130] The region on the first surface of the substrate where the cell scaffold is disposed may or may not be subjected to low cell adhesion treatment.
[0131] A cell culture substrate comprising a cell scaffold containing a peptide-containing resin can be prepared, for example, by the following method (A) or (B). The following method (A) is an example of a method for preparing a cell culture substrate using a method for synthesizing a peptide-containing resin by a liquid phase method, and the following method (B) is an example of a method for preparing a cell culture substrate using a method for synthesizing a peptide-containing resin by a solid phase method.
[0132] (A) A solution containing a synthetic resin (hereinafter sometimes referred to as "synthetic resin X") having a functional group reactive with an amino group or a functional group reactive with a carboxyl group and a peptide is prepared. Synthetic resin X is reacted with the peptide to obtain a peptide-containing resin. The solution containing the peptide-containing resin and a solvent is applied in dots onto the first surface of the substrate, and the solvent is then volatilized.
[0133] (B) A solution containing a synthetic resin (synthetic resin X) having a functional group reactive with an amino group or a functional group reactive with a carboxyl group is prepared. The solution containing synthetic resin X is applied in the form of dots onto the first surface of the substrate. A liquid containing a peptide is added onto the first surface of the substrate, and the synthetic resin X and the peptide are reacted.
[0134] Examples of the synthetic resin X include a (meth)acrylate polymer and a polyvinyl acetal derivative having a linker bonded thereto. Methods for applying the solution in dots onto the first surface of the substrate include a method using a dispenser, a method using an inkjet device, a method using a stamp, and a method using a pipette.
[0135] A cell culture substrate comprising a cell scaffold material containing a cell adhesive protein can be produced, for example, by applying a solution containing the cell adhesive protein in the form of dots onto a first surface of the substrate, and then evaporating the solvent.
[0136] [Method for producing hematopoietic progenitor cells and method for producing leukocytes] (Cell mass formation step) The method for producing hematopoietic progenitor cells and method for producing leukocytes according to the present invention comprise a step of culturing pluripotent stem cells using the cell culture substrate and forming cell masses on the surface of the cell scaffold (cell mass formation step).
[0137] Examples of the pluripotent stem cells include induced pluripotent stem cells (iPS cells), embryonic stem cells (ES cells), and embryonic germ stem cells (EG cells).
[0138] From the viewpoint of application in the fields of regenerative medicine and drug discovery, the pluripotent stem cells are preferably iPS cells.
[0139] The cell aggregate forming step preferably includes the following steps (a), (b) and (c) in this order.
[0140] Step (a): seeding pluripotent stem cells onto the cell culture substrate, Step (b): culturing the pluripotent stem cells, and Step (c): forming cell clusters on the surface of the cell scaffold.
[0141] <Step (a)> In step (a), the pluripotent stem cells that have been subjected to maintenance culture are preferably seeded onto the cell culture substrate.
[0142] The seeding density of the pluripotent stem cells in step (a) is 1 cm / cm2 of the area of the first surface of the substrate. 2 In contrast, the seeding density may be 5,000 cells or more, 10,000 cells or more, 15,000 cells or more, 80,000 cells or less, 65,000 cells or less, or 50,000 cells or less. In the present invention, hematopoietic progenitor cells or leukocytes can be stably obtained whether the seeding density is relatively high or relatively low.
[0143] <Step (b)> In step (b), the pluripotent stem cells seeded in step (a) are cultured. Conventional media used for culturing pluripotent stem cells can be used as the medium for culturing pluripotent stem cells in step (b). The medium is preferably a liquid medium. Commercially available media or home-prepared media may be used. Commercially available media include "Stem Fit AK03N" and "Stem Fit AK02N" manufactured by Ajinomoto Co., Inc., "TeSR-E8," "mTeSR1," and "mTeSR Plus" manufactured by STEMCELL Technologies, Inc., and "StemFlex" and "Essential 8" manufactured by Gibco. The medium may contain a ROCK (Rho-associated kinase)-specific inhibitor or may not contain a ROCK-specific inhibitor. Alternatively, a medium containing a ROCK-specific inhibitor or a medium not containing a ROCK-specific inhibitor may be used depending on the culture time.
[0144] The culture temperature in step (b) is preferably 35° C. or higher, and preferably 38° C. or lower. 2 The concentration is preferably 4% or more, and preferably 6% or less. For example, the culture conditions in step (b) are 37°C and CO 2 The condition is a concentration of 5%. The culture time in step (b) can be, for example, 2 to 8 days (preferably 4 days). During the culture in step (b), the medium may or may not be replaced. When the medium is replaced, it can be replaced with a fresh medium, for example, once a day.
[0145] <Step (c)> In step (c), cell clusters can be obtained from pluripotent stem cells. By performing step (b), cell clusters are formed on the surface of the cellular scaffold. More specifically, by performing step (b), cell clusters are formed on the upper surface of the cellular scaffold. The cell clusters are preferably cell clusters containing pluripotent stem cells. In step (c), cell clusters are usually formed according to the size of the upper surface of the cellular scaffold.
[0146] (Differentiation induction step) The method for producing hematopoietic progenitor cells according to the present invention includes a step (differentiation induction step) of inducing differentiation of the obtained cell mass into a cell population containing hematopoietic progenitor cells (a cell group containing hematopoietic progenitor cells).
[0147] The method for producing leukocytes according to the present invention includes a step of inducing differentiation of the obtained cell mass into a cell population containing monocytes, lymphocytes, or granulocytes (a cell group containing monocytes, lymphocytes, or granulocytes) (differentiation induction step). The differentiation induction step in the method for producing leukocytes according to the present invention may be a step of differentiating into a cell population containing monocytes, a step of differentiating into a cell population containing lymphocytes, or a step of differentiating into a cell population containing granulocytes.
[0148] In this specification, the common features of the differentiation induction step in the method for producing hematopoietic progenitor cells and the differentiation induction step in the method for producing leukocytes will be simply referred to as the "differentiation induction step."
[0149] In the differentiation induction step, differentiation induction is carried out using the cell clusters obtained in the cell cluster formation step.
[0150] The differentiation induction conditions and culture conditions in the differentiation induction step can be conventionally known conditions for differentiating pluripotent stem cells into hematopoietic progenitor cells or leukocytes. The differentiation induction step may use the same cell culture substrate as used in the cell mass formation step, or a different cell culture substrate than that used in the cell mass formation step. From the viewpoint of inducing differentiation without detaching the resulting cell masses from the cell culture substrate, it is preferable to use the same cell culture substrate as used in the cell mass formation step at least at the start of the differentiation induction step. From the viewpoint of inducing differentiation without detaching pre-differentiating or differentiated cells from the cell culture substrate, it is preferable to use the same cell culture substrate as used in the cell mass formation step at all points in the differentiation induction step.
[0151] Figure 2 shows an example of a flow chart for inducing differentiation of iPS cells into hematopoietic progenitor cells and then into leukocytes (monocytes, lymphocytes, or granulocytes). Tables 1 to 3 show examples of liquid media that can be used, examples of differentiation-inducing factors that can be used, and approximate culture periods for each step of the differentiation-inducing process. Table 4 also shows the official names of the differentiation-inducing factors. The names of each step (steps (1) to (5B)) in Figure 2 and Tables 1 to 3 correspond to the names of the steps described below.
[0152]
[0153]
[0154]
[0155]
[0156] In the method for producing hematopoietic progenitor cells, the differentiation induction step preferably comprises the following steps (1), (2) and (3) in this order:
[0157] Step (1): Culturing the obtained cell mass in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing mesoderm. Step (2): Culturing the obtained cell population containing mesoderm in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing hemogenic endothelial cells. Step (3): Culturing the obtained cell population containing hemogenic endothelial cells in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing hematopoietic progenitor cells.
[0158] <Step (1)> In step (1), the cell clusters obtained in the cell cluster formation step are cultured. Step (1) is preferably a step of culturing the obtained cell clusters in a state of adhesion to the surface of the cell scaffold in the presence of a medium containing a differentiation-inducing factor, to obtain a cell population containing mesoderm. Step (1) is preferably a step of inducing differentiation of pluripotent stem cells contained in the cell clusters into a cell population containing mesoderm.
[0159] <Step (2)> In step (2), the mesoderm-containing cell population obtained in step (1) is cultured. Step (2) is preferably a step of culturing the obtained mesoderm-containing cell population in an adherent state on the surface of the cell scaffold in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing hemogenic endothelial cells. Step (2) is preferably a step of inducing differentiation of the mesoderm into a cell population containing hemogenic endothelial cells.
[0160] <Step (3)> In step (3), the cell population containing hemogenic endothelial cells obtained in step (2) is cultured. Step (3) is preferably a step of culturing the obtained cell population containing hemogenic endothelial cells in an adherent state on the surface of the cell scaffold in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing hematopoietic progenitor cells. Step (3) is preferably a step of inducing differentiation of the hemogenic endothelial cells into a cell population containing hematopoietic progenitor cells.
[0161] Whether or not the cells have been induced to become hematopoietic progenitor cells can be confirmed, for example, by observing the cell morphology or by analyzing the expression of differentiation markers in the cells using a flow cytometer. Known differentiation markers for hematopoietic progenitor cells include CD34 and CD43. For example, the induction to become hematopoietic progenitor cells can be confirmed by the simultaneous expression of CD34 and CD43.
[0162] The culture temperatures in steps (1), (2), and (3) are preferably 35° C. or higher and preferably 38° C. or lower. 2 The concentrations are preferably 4% or more and 6% or less, respectively. For example, the culture conditions for steps (1), (2), and (3) are 37° C. and CO 2 The condition is a concentration of 5%. The total culture time for steps (1), (2), and (3) can be, for example, 4 to 13 days. During the culture in steps (1), (2), and (3), the medium may or may not be replaced. When the medium is replaced, it can be replaced with a fresh medium, for example, once every two days.
[0163] Hematopoietic progenitor cells are induced, for example, within about 7 days from the start of the culture in step (1), and a cell population containing hematopoietic progenitor cells can be obtained. The obtained cell population containing hematopoietic progenitor cells can be induced to differentiate into cell populations containing various blood cells under conventionally known differentiation induction conditions and culture conditions. For example, leukocytes can be produced by inducing the differentiation of the obtained cell population containing hematopoietic progenitor cells into a cell population containing monocytes, lymphocytes, or granulocytes.
[0164] In the method for producing leukocytes, the differentiation induction step preferably includes the following step (4A) or step (4B) in addition to the above steps (1), (2), and (3). In the method for producing leukocytes, the differentiation induction step may include the above steps (1), (2), (3), and the following step (4A) in this order, or may include the above steps (1), (2), (3), and the following step (4B) in this order.
[0165] Step (4A): A step of culturing the obtained cell population containing hematopoietic progenitor cells in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing myeloid progenitor cells.
[0166] Step (4B): A step of culturing the obtained cell population containing hematopoietic progenitor cells in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing lymphoid progenitor cells.
[0167] <Step (4A)> In step (4A), the cell population containing hematopoietic progenitor cells obtained in step (3) is cultured. Step (4A) may be a step of culturing the obtained cell population containing hematopoietic progenitor cells in a state of adhesion to the surface of the cell scaffold in the presence of a medium containing a differentiation-inducing factor, to obtain a cell population containing myeloid progenitor cells. Step (4A) is preferably a step of inducing differentiation of the hematopoietic progenitor cells into a cell population containing myeloid progenitor cells.
[0168] <Step (4B)> In step (4B), the cell population containing hematopoietic progenitor cells obtained in step (3) is cultured. Step (4B) preferably comprises the steps of recovering floating cells from the obtained cell population containing hematopoietic progenitor cells, and culturing the recovered cells in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing lymphoid progenitor cells. In this case, the efficiency of inducing differentiation into lymphocytes can be further increased, and in particular, the efficiency of inducing differentiation into T cells can be further increased. Step (4B) is preferably a step of inducing differentiation of hematopoietic progenitor cells into a cell population containing lymphoid progenitor cells.
[0169] The method for producing leukocytes preferably comprises a step of inducing differentiation of a cell population containing hematopoietic progenitor cells obtained by the method for producing hematopoietic progenitor cells described above into a cell population containing monocytes, lymphocytes, or granulocytes. The method for producing leukocytes preferably produces leukocytes containing at least one type of monocytes, lymphocytes, and granulocytes. The method for producing leukocytes is preferably any one of a method for producing monocytes, a method for producing granulocytes, and a method for producing lymphocytes. The method for producing leukocytes may be a method for producing monocytes, a method for producing granulocytes, or a method for producing lymphocytes.
[0170] When the method for producing leukocytes is a method for producing monocytes, the differentiation induction step preferably comprises the step (4A) and the following step (5Aa). That is, the differentiation induction step preferably comprises the step (1), the step (2), the step (3), the step (4A), and the following step (5Aa) in this order.
[0171] Step (5Aa): A step of culturing the obtained cell population containing myeloid progenitor cells in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing monocytes.
[0172] <Step (5Aa)> In step (5Aa), it is preferable to culture the cell population containing myeloid progenitor cells obtained in step (4A). Step (5Aa) may be a step of culturing the obtained cell population containing myeloid progenitor cells in a state of adhesion to the surface of the cell scaffold in the presence of a medium containing a differentiation-inducing factor, to obtain a cell population containing monocytes. Step (5Aa) is preferably a step of inducing differentiation of the myeloid progenitor cells into a cell population containing monocytes.
[0173] Whether or not the cells have been induced to become monocytes can be confirmed, for example, by observing the cell morphology or by analyzing the expression of differentiation markers in the cells using a flow cytometer. Known monocyte differentiation markers include CD14.
[0174] The obtained monocytes can also be differentiated into a cell population containing phagocytes such as dendritic cells and macrophages. The method for producing leukocytes may further include a step of culturing the obtained cell population containing monocytes in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing phagocytes.
[0175] When the method for producing leukocytes is a method for producing granulocytes, the differentiation induction step preferably comprises the step (4A) and the following step (5Ab). That is, the differentiation induction step preferably comprises the step (1), the step (2), the step (3), the step (4A), and the following step (5Ab) in this order.
[0176] Step (5Ab): A step of culturing the obtained cell population containing myeloid progenitor cells in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing granulocytes.
[0177] <Step (5Ab)> In step (5Ab), it is preferable to culture the cell population containing myeloid progenitor cells obtained in step (4A). Step (5Ab) may be a step of culturing the obtained cell population containing myeloid progenitor cells in a state of adhesion to the surface of the cell scaffold in the presence of a medium containing a differentiation-inducing factor, to obtain a cell population containing granulocytes. Step (5Ab) is preferably a step of inducing differentiation of the myeloid progenitor cells into a cell population containing granulocytes. The granulocytes are preferably at least one type of neutrophils, eosinophils, and basophils.
[0178] Whether or not the cells have been induced to become granulocytes can be confirmed, for example, by observing the cell morphology or by analyzing the expression of differentiation markers in the cells using a flow cytometer. Known examples of granulocyte differentiation markers include CD15 and CD62L.
[0179] When the method for producing leukocytes is a method for producing lymphocytes, the differentiation induction step preferably comprises the step (4B) and the following step (5B). That is, the differentiation induction step preferably comprises the step (1), the step (2), the step (3), the step (4B), and the following step (5B) in this order.
[0180] Step (5B): A step of culturing the obtained cell population containing lymphoid progenitor cells in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing lymphocytes.
[0181] <Step (5B)> In step (5B), it is preferable to culture the cell population containing lymphoid progenitor cells obtained in step (4B). Step (5B) is preferably a step of inducing differentiation of the lymphoid progenitor cells into a cell population containing lymphocytes. The lymphocytes are preferably at least one type of B cells, T cells, and NK cells. When a cell population containing T cells is obtained, step (5B) is preferably performed in the presence of a Notch ligand.
[0182] Whether or not lymphocytes have been induced can be confirmed, for example, by observing the cell morphology or by analyzing the expression of differentiation markers in the cells using a flow cytometer. Known lymphocyte differentiation markers include CD3, CD4, and CD8 (T cell differentiation markers), and CD56 (NK cell differentiation marker).
[0183] The present invention will be specifically described below with reference to examples, but the present invention is not limited to the following examples.
[0184] (Example 1) (1) Preparation of cell culture substrate A 12-well plate (manufactured by Corning Incorporated, surface treatment: tissue culture treatment (TC treatment), bottom area of each well: 3.8 cm) was used as the substrate (cell culture substrate body). 2 (referred to as 12wP in the table) was prepared. Furthermore, a polyvinyl acetal resin with an acetalization degree (butyralization degree) of 65 mol%, a hydroxyl group content of 32 mol%, and an acetyl group content of 3 mol% was prepared. 30 parts by weight of acrylic acid and 70 parts by weight of polyvinyl acetal resin were dissolved in 255 parts by weight of tetrahydrofuran to obtain a polymer mixture solution. 0.015 parts by weight of Perbutyl O (manufactured by NOF Corporation) was dissolved in the obtained polymer mixture solution, and the mixture was reacted at 90°C for 6 hours. The reacted solution was then mixed with 30,000 parts by weight of water. The resulting precipitate was vacuum-dried at 80°C for 3 hours to prepare a polyvinyl acetal resin having a linker (acrylic acid) (a polyvinyl butyral resin having a linker). Hereinafter, the "polyvinyl acetal resin having a linker" may be referred to as "polyvinyl acetal resin (X)."
[0185] The obtained polyvinyl acetal resin (X) and ethanol were mixed together, and the resulting mixture was applied in dots onto the first surface of the substrate using a dispenser, and then dried to volatilize the solvent.
[0186] A cyclic peptide having the amino acid sequence Arg-Gly-Asp-Phe-Lys (5 amino acid residues, Arg and Lys bonded to form a cyclic skeleton, Phe is in the D-configuration, c-RGDfK) was prepared. 10 parts by weight of this peptide and 10 parts by weight of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (condensing agent) were added to 80 parts by weight of methanol to prepare a peptide-containing liquid. This peptide-containing liquid was added to the first surface of the substrate and reacted at 30°C to cause dehydration condensation between the carboxyl group in the structural unit derived from acrylic acid of the polyvinyl acetal resin (X) and the amino group of Lys in the peptide.
[0187] In this way, a cell culture substrate was obtained that included a substrate and a cell scaffold material arranged in a dot pattern on the first surface of the substrate. The cell scaffold material contained a peptide-containing polyvinyl acetal resin (peptide-containing resin).
[0188] Details of the obtained cell culture substrate are shown in the table below. The cell scaffold material prepared as described above is referred to as "PVB-AA (composition 1)" in the table below.
[0189] (2) Cell Culture Differentiation induction media A1 to E1 shown in the table below were prepared.
[0190]
[0191] (2-1) Maintenance Culture of iPS Cells The iPS cell line (line 053018A, referred to as line 1 in the table below) established from human fibroblasts by the Kyoto University iPS Cell Research Foundation was used. The iPS cells were seeded onto a 6-well plate whose bottom was entirely coated with laminin, and maintained at 37°C and CO using StemFit AK03N medium (Ajinomoto Co., Inc.). 2 The culture was maintained at a concentration of 5%.
[0192] (2-2) iPS Cell Culturing (Cell Mass Formation Step) The iPS cells maintained in culture were detached from the 6-well plate using a detachment agent (TrypLE Select, manufactured by Thermo Fisher Scientific) at 37°C for 10 minutes. The detached iPS cells were diluted with StemFit AK03N medium containing 10 μM of ROCK inhibitor (Y-27632) and then seeded onto the prepared cell culture substrate at a seeding density of 8.0 × 10 4 The cells were seeded at 1.5 mL per well. 2 The cells were cultured in the presence of StemFit AK03N medium containing 10 μM of ROCK inhibitor (Y-27632) at a concentration of 5%. The day after seeding, the medium was replaced with StemFit AK03N medium without ROCK inhibitor (Y-27632). Then, the cells were incubated at 37°C and CO 2 The cells were further cultured for 3 days at a concentration of 5%, and cell clusters (cell clusters containing iPS cells) were formed on the upper surface of the cell scaffold material in the cell culture substrate.
[0193] (2-3) Differentiation induction step (step (1), Day 0 to Day 2) The obtained cell clusters containing iPS cells were washed with 1.6 mL of Essential-8 medium. Next, 1.6 mL of Medium A1 was added to the cell culture substrate, and the cell clusters were incubated at 37°C and CO with the cell clusters attached to the surface of the cell scaffold. 2 The cells were cultured for 2 days at a concentration of 5%. In this way, a cell population containing mesoderm was obtained.
[0194] (2-4) Differentiation Induction Step (Step (2), Day 2 to Day 4) Medium A1 was removed from the cell culture substrate, and 1.6 mL of medium B1 was added to the cell culture substrate. The cells were cultured at 37°C and CO in a state where a mesoderm-containing cell population was attached to the surface of the cell scaffold. 2 The cells were cultured at a concentration of 5% for 2 days, thus obtaining a cell population containing hemogenic endothelial cells.
[0195] (2-5) Differentiation Induction Step (Step (3), Day 4 to Day 7) Medium B1 was removed from the cell culture substrate, and 3.2 mL of medium C1 was added to the cell culture substrate. The cell culture substrate was then incubated at 37°C and CO in a state where a cell population containing hemogenic endothelial cells was adhered to the surface of the cell scaffold.2 The cells were cultured at a concentration of 5% for 3 days, thereby obtaining a cell population containing hematopoietic progenitor cells.
[0196] (2-6) Differentiation induction step (step (4A), Day 7 to Day 10) Medium C1 was removed from the cell culture substrate, and 2 mL of medium D1 was added to the cell culture substrate. The cell culture substrate was then incubated at 37°C and CO in a state where a cell population containing hematopoietic progenitor cells was adhered to the surface of the cell scaffold. 2 The cells were cultured at a concentration of 5% for 3 days, thereby obtaining a cell population containing myeloid progenitor cells.
[0197] (2-7) Differentiation induction step (step (5Aa), Day 10 to Day 15) Medium D1 was removed from the cell culture substrate, and 1.6 mL of medium E1 was added to the cell culture substrate. The cell culture substrate was incubated at 37°C and CO in a state where a cell population containing myeloid progenitor cells was adhered to the surface of the cell scaffold. 2 The cells were cultured at a concentration of 5%. During the culture, half of the liquid in the cell culture substrate was replaced with fresh Medium E1 every two days. The floating cells collected during the medium replacement were cultured in non-TC culture-treated plates (manufactured by Corning). Five days after the start of culture in Medium E1, the supernatant containing the floating cells was collected. Next, a detachment agent (TrypLE Select, manufactured by Thermo Fisher Scientific) was used to pipette and detach the cells, and all the cells in the cell culture substrate were collected.
[0198] (Examples 2 to 5) Cell culture substrates were obtained in the same manner as in Example 1, except that the configuration of the cell scaffold material in the cell culture substrate was changed as shown in the table below. Furthermore, using the obtained cell culture substrates, "(2) Cell culture" was carried out in the same manner as in Example 1.
[0199] (Example 6) As the substrate (cell culture substrate body) of the cell culture substrate, a 24-well plate (manufactured by Corning Incorporated, surface treatment: ultra-low adhesion treatment, bottom area of each well: 1.9 cm 2, shown as 24wP in the table), was used. The composition of the cell scaffold material was changed as shown in the table below. Other than these, a cell culture substrate was obtained in the same manner as in Example 1. Furthermore, by using the obtained cell culture substrate and setting the seeding density of iPS cells on the cell culture substrate to 4.0 × 10 4 "(2) Cell culture" was carried out in the same manner as in Example 1, except that the number of cells / well was changed to 1 / 2 and the amount of medium was reduced to 1 / 2.
[0200] (Comparative Example 1) A cell culture substrate was obtained in the same manner as in Example 1, except that a cell scaffold material was disposed over the entire first surface of the substrate (cell culture substrate main body). Furthermore, using the obtained cell culture substrate, "(2) Cell culture" was carried out in the same manner as in Example 1.
[0201] (Example 7) (1) Preparation of cell culture substrate A 12-well plate (manufactured by Corning Incorporated, surface treatment: tissue culture treatment (TC treatment), bottom area of each well: 3.8 cm) was used as the substrate (cell culture substrate body). 2 In addition, a polyvinyl acetal resin (X) was prepared in the same manner as in Example 1.
[0202] Dimethylformamide (DMF) was prepared as the first solvent. Dimethylformamide (DMF) was prepared as the second solvent. A cyclic peptide having the amino acid sequence Arg-Gly-Asp-Phe-Lys (five amino acid residues, Arg and Lys bonded to form a cyclic skeleton, Phe is in the D-configuration, c-RGDfK) was prepared as the peptide. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was prepared as the condensing agent. 1000 parts by weight of the first solvent was mixed with 50 parts by weight of polyvinyl acetal resin (X) and 2 parts by weight of the peptide to prepare a first solution. 1000 parts by weight of the second solvent was mixed with 1 part by weight of the condensing agent to prepare a second solution. The first and second solutions were mixed to prepare a solution containing polyvinyl acetal resin (X), the peptide, and the condensing agent.
[0203] The obtained solution was reacted at 40°C for 2 hours to cause dehydration condensation between the carboxyl group in the structural unit derived from acrylic acid of the polyvinyl acetal resin (X) and the amino group of Lys of the peptide, thereby obtaining a solution containing a peptide-containing polyvinyl acetal resin (peptide-containing resin).
[0204] The resulting solution containing the peptide-containing polyvinyl acetal resin was diluted 100-fold with DMF and washed by adding it dropwise at a rate of 0.3 mL / min to a column packed with an ion-exchange resin (manufactured by Organo Corporation). The washed solution was vacuum dried at 60°C for 3 hours to obtain a dried product, which was then dissolved in butanol (alcohol solvent). Five parts by weight of acetic acid (pH adjuster) was added to 100 parts by weight of butanol (alcohol solvent) to obtain a solution containing the peptide-containing polyvinyl acetal resin and butanol (alcohol solvent).
[0205] The resulting solution containing the peptide-containing polyvinyl acetal resin and butanol (alcohol solvent) was applied in dots onto the first surface of the substrate using an inkjet device, and then dried to volatilize the solvent.
[0206] In this way, a cell culture substrate was obtained that included a substrate and a cell scaffold material arranged in a dot pattern on the first surface of the substrate. The cell scaffold material contained a peptide-containing polyvinyl acetal resin (peptide-containing resin).
[0207] Details of the obtained cell culture substrate are shown in the table below. The cell scaffold material prepared as described above is referred to as "PVB-AA (composition 2)" in the table below.
[0208] (2) Cell Culture "(2) Cell culture" was carried out in the same manner as in Example 1, except that the obtained cell culture substrate was used and the following changes were made.
[0209] (a) The 201B7 strain (referred to as strain 2 in the table below) was used as the iPS cells. (b) Instead of media A1 to E1, media A2 to E2 shown in the table below were used.
[0210]
[0211] (Example 8) A cell culture substrate was obtained in the same manner as in Example 7, except that the configuration of the cell scaffold material in the cell culture substrate was changed as shown in the table below. Using the obtained cell culture substrate, "(2) Cell culture" was carried out in the same manner as in Example 7.
[0212] Example 9 (1) Preparation of Cell Culture Substrate A mixture of laminin ("iMatrix-511" manufactured by Nippi Corporation) and phosphate-buffered saline (PBS) was applied in dots to the first surface of the substrate using a pipette, and then dried to volatilize the solvent. In this way, a cell culture substrate was obtained comprising a substrate and a cell scaffold material arranged in dots on the first surface of the substrate. The cell scaffold material contained laminin.
[0213] (2) Cell Culturing Using the obtained cell culture substrate, "(2) Cell culturing" was carried out in the same manner as in Example 7.
[0214] (Comparative Example 2) A cell culture substrate was obtained in the same manner as in Example 7, except that a cell scaffold material was disposed over the entire first surface of the substrate (cell culture substrate main body). Using the obtained cell culture substrate, "(2) Cell culture" was carried out in the same manner as in Example 7.
[0215] (Evaluation: Examples 1 to 9 and Comparative Examples 1 and 2) (1) Presence of floating cells On day 5 (Day 15) after the start of culture in medium E1 or medium E2, the cell culture substrate was observed under a microscope to confirm the presence or absence of floating cells. If floating cells were present, it could be assumed that monocytes had been produced.
[0216] <Evaluation criteria for the presence of floating cells> ○: Floating cells can be confirmed ×: Floating cells cannot be confirmed
[0217] (2) Number of Recovered Cells The number of recovered cells was measured using a cell counter ("NC3000" manufactured by M-Techno Systems).
[0218] (3) Area of the top surface of the cell scaffold: 10 mm 2 The number of recovered cells per 10 mm2 of the upper surface of the cell scaffold was calculated by dividing the number of recovered cells by the area of the upper surface of the cell scaffold. 2 The number of recovered cells per well was calculated.
[0219] (4) Ratio of CD14-Positive Cells The collected cells were labeled with an anti-CD14 antibody (manufactured by BD Pharmingen) and then measured and analyzed using a flow cytometer ("SA3800 Cell Analyzer" manufactured by Sony Corporation).
[0220] The percentage of CD14-positive cells was calculated using the following formula.
[0221] Percentage of CD14-positive cells (%) = A / B x 100 A: Number of cells (cells) having the CD14 marker detected by measurement with a flow cytometer B: Number of cells (cells) measured with a flow cytometer
[0222] (5) Differentiation Induction of CD14-Positive Cells into Macrophage-Like Cells The CD14-positive cells obtained in Examples 1 to 6 were evaluated as follows. TexMACS medium (Miltenyi Biotec) supplemented with 50 ng / mL M-CSF (granulocyte-macrophage colony-stimulating factor, Miltenyi Biotec) was prepared. 4 mL of this medium was added to the cell culture substrate, and CD14-positive cells were cultured for 7 days. During the culture, half of the liquid in the cell culture substrate was replaced with fresh medium every two days. After the culture, the cells were examined for differentiation into macrophage-like cells using the following method.
[0223] (a) After the culture, the cells were labeled with an anti-CD11b antibody and then measured using a flow cytometer. As a result, cells expressing CD11b, a macrophage marker, were confirmed in all examples.
[0224] (b) The cultured cells were further cultured for 24 hours in 4 mL of TexMACS medium supplemented with 20 ng / mL IL-4. The cultured cells were then labeled with anti-CD163 and anti-CD206 antibodies and measured using a flow cytometer. As a result, cells expressing CD163 and CD206, which are markers of M2 macrophages, were confirmed in all Examples. Furthermore, cytokine production was confirmed by ELISA in all Examples, confirming the production of IL-10.
[0225] The details and results are shown in the table below. In the column for culture medium conditions in the table below, "Condition 1" means the condition using culture media A1 to E1, and "Condition 2" means the condition using culture media A2 to E2. In the table below, ".E+0N" means "×10 N ", for example, "3.2.E+06" means 3.2 × 10 6 The evaluation results of "induction of differentiation of CD14-positive cells into macrophage-like cells" in Examples 1 to 6 were judged as "good" based on the results of (a) and (b) above.
[0226]
[0227]
[0228] (Examples 10 and 11) (1) Preparation of cell culture substrates Cell culture substrates were obtained in the same manner as in Example 7, except that the structure of the cell scaffold material in the cell culture substrate was changed as shown in the table below.
[0229] (2) Cell Culture "(2) Cell culture" was carried out in the same manner as in Example 7, except that the obtained cell culture substrate was used and the following changes were made.
[0230] (a) 253G1 (referred to as strain 3 in the table below) iPS cells were used. (b) The seeding density of iPS cells on the prepared cell culture substrate was 2.0 × 10 4 cells / well, 4.0×10 4 cells / well, 8.0×10 4 cells / well, 1.6×10 5Experiments were conducted under four conditions: 1000 cells / well. (c) Using the above four seeding densities, the steps from "(2-1) iPS cell maintenance culture" to "(2-5) differentiation induction step (step (3), Day 4 to Day 7)" were carried out under the same conditions as in Example 7. Culture in medium C2 was then continued for 5 days. During culture in medium C2, half of the liquid in the cell culture substrate was replaced with fresh medium C2 every two days. After collecting the supernatant containing the floating cells on Day 9, the cells were pipetted and detached using a detachment agent (TrypLE Select, manufactured by Thermo Fisher Scientific) to recover all the cells in the cell culture substrate.
[0231] (Comparative Example 3) A cell culture substrate was obtained in the same manner as in Example 10, except that a cell scaffold material was disposed over the entire first surface of the substrate (cell culture substrate main body). Using the obtained cell culture substrate, "(2) Cell culture" was carried out in the same manner as in Example 10.
[0232] (Example 12) (1) Preparation of cell culture substrate A 24-well plate (manufactured by Corning Incorporated, surface treatment: tissue culture treatment (TC treatment), bottom area of each well: 1.9 cm) was used as the substrate (cell culture substrate body) of the cell culture substrate. 2 A cell culture substrate was obtained in the same manner as in Example 7, except that a cellulose acylate 100% cellulose acylate (referred to as 24wP in the table) was used and the composition of the cell scaffold material was changed as shown in the table below.
[0233] (2) Cell Culture "(2) Cell culture" was carried out in the same manner as in Example 10, except that the obtained cell culture substrate was used.
[0234] (Example 13) (1) Preparation of cell culture substrate A 24-well plate (manufactured by Corning Incorporated, surface treatment: ultra-low adhesion treatment, bottom area of each well: 1.9 cm) was used as the substrate (cell culture substrate body) of the cell culture substrate. 2 A cell culture substrate was obtained in the same manner as in Example 7, except that a cellulose acylate 100% cellulose acylate (referred to as 24wP in the table) was used and the composition of the cell scaffold material was changed as shown in the table below.
[0235] (2) Cell Culturing Using the obtained cell culture substrate, "(2) Cell culturing" was carried out in the same manner as in Example 12.
[0236] (Evaluation: Examples 10 to 13 and Comparative Example 3) (1) Presence of floating cells On day 5 after the start of culture in medium C2, the cell culture substrate was observed under a microscope to confirm the presence or absence of floating cells. If floating cells were present, it could be assumed that hematopoietic progenitor cells had been produced.
[0237] <Evaluation criteria for the presence of floating cells> ○: Floating cells can be confirmed ×: Floating cells cannot be confirmed
[0238] (2) Number of Recovered Cells The number of recovered cells was measured using a cell counter ("NC3000" manufactured by M-Techno Systems).
[0239] (3) Number of CD34 / CD43-Positive Cells The collected cells were labeled with an anti-CD34 antibody (manufactured by BD Pharmingen) and an anti-CD43 antibody (manufactured by BD Pharmingen), and then measured and analyzed using a flow cytometer (Sony SA3800 Cell Analyzer). The number of cells that were positive for both CD34 and CD43 (number of CD34 / CD43-positive cells) was calculated.
[0240] Details and results are shown in the table below. In the table below, "Condition 2" in the column for culture medium conditions means conditions using culture media A2 to E2. In addition, "E+0N" in the table below means "×10 to the Nth power," for example, "3.2E+06" is 3.2×10 6 means.
[0241]
[0242]
[0243] As shown in Table 9, it can be seen that in Examples 10 and 11, hematopoietic progenitor cells were stably produced even at a high seeding density compared to Comparative Example 3. Furthermore, as shown in Table 10, it can be seen that, under all seeding conditions, in Example 13, which used a substrate subjected to ultra-low adhesion treatment, more hematopoietic progenitor cells were obtained than in Example 12.
[0244] (Example 14) (1) Preparation of cell culture substrate A cell culture substrate was obtained in the same manner as in Example 7, except that the structure of the cell scaffold material was changed as shown in the table below.
[0245] (2) Cell Culture The steps from "(2-1) iPS cell maintenance culture" to "(2-5) differentiation induction step (step (3), Day 4 to Day 7)" were carried out in the same manner as in Example 7, except that the obtained cell culture substrate was used and StemFit AK02N was used instead of StemFit AK03N.
[0246] Furthermore, the following differentiation-inducing media F1 and G1 were prepared.
[0247] Medium F1: StemSpan Lymphoid Progenitor Expansion Medium (STEMCELL Technologies)
[0248] Medium G1: StemSpan NK Cell Differentiation Medium (STEMCELL Technologies)
[0249] (2-6) Differentiation induction step (step (4B), Day 7 to Day 21) Medium C2 was removed from the cell culture substrate, and 1.6 mL of medium F1 was added to the cell culture substrate. The cell culture substrate was incubated at 37°C and CO in a state where a cell population containing hematopoietic progenitor cells was adhered to the surface of the cell scaffold. 2 The cells were cultured for 14 days at a concentration of 5%. Half of the liquid in the cell culture substrate was replaced with fresh Medium F1 every three days. In this way, a cell population containing lymphoid progenitor cells was obtained.
[0250] (2-7) Differentiation induction step (step (5B), Day 21 to Day 44) The medium F1 in the cell culture substrate was removed, and 1.6 mL of medium G1 was added to the cell culture substrate. The cell culture substrate was then incubated at 37°C and CO in a state where a cell population containing lymphoid progenitor cells was adhered to the surface of the cell scaffold. 2The cells were cultured at a concentration of 5%. During the culture, half of the liquid in the cell culture substrate was replaced with fresh G1 medium every three days. The suspended cells collected during the medium replacement were cultured in non-TC culture-treated plates (manufactured by Corning). On Day 44, the supernatant containing the suspended cells and the cells detached by pipetting were collected. Next, a detachment agent (TrypLE Select, manufactured by Thermo Fisher Scientific) was used to pipette and detach the cells, and all the cells in the cell culture substrate were collected. In this way, a cell population containing lymphocytes (NK cells) was obtained.
[0251] (Example 15) A cell culture substrate was obtained in the same manner as in Example 14, except that the configuration of the cell scaffold material in the cell culture substrate was changed as shown in the table below. Using the obtained cell culture substrate, "(2) Cell culture" was carried out in the same manner as in Example 14.
[0252] (Comparative Example 4) A cell culture substrate was obtained in the same manner as in Example 7, except that a cell scaffold material was disposed over the entire first surface of the substrate (cell culture substrate main body). Using the obtained cell culture substrate, "(2) Cell culture" was carried out in the same manner as in Example 14.
[0253] (Evaluation: Examples 14 and 15 and Comparative Example 4) (1) Presence of floating cells On day 23 (Day 44) after the start of culture in Medium G1, the cell culture substrate was observed under a microscope to confirm the presence or absence of floating cells. If floating cells were present, it could be assumed that lymphocytes (NK cells) were being produced.
[0254] <Evaluation criteria for the presence of floating cells> ○: Floating cells can be confirmed ×: Floating cells cannot be confirmed
[0255] (2) Percentage of cells detached by pipetting Before using the detachment agent, the percentage of cells detached from the cell culture substrate by pipetting (number of cells detached by pipetting / number of cells adhered to the surface of the cell scaffold before pipetting × 100 (%)) was visually confirmed.
[0256] (3) Number of iPS cells on Day 0 The number of iPS cells (cells / well) on Day 0 was measured using a cell counter ("NC3000" manufactured by MS Techno Systems).
[0257] (4) Number of CD56-Positive Cells The collected cells were labeled with an anti-CD56 antibody (manufactured by BD Pharmingen), and then measured and analyzed using a flow cytometer ("SA3800 Cell Analyzer" manufactured by Sony Corporation).
[0258] The percentage of CD56-positive cells was calculated using the following formula, and the number of CD56-positive cells (cells / well) was calculated from the number of cells collected on Day 44.
[0259] Percentage of CD56-positive cells (%) = A / B x 100 A: Number of cells (cells) having the CD56 marker detected by measurement with a flow cytometer B: Number of cells (cells) measured with a flow cytometer
[0260] Details and results are shown in the table below. In the table below, "Condition 3" in the column for culture medium conditions refers to conditions using culture media A2 to C2, F1, and G1. In the table below, ".E+0N" means "×10 to the Nth power," for example, "3.2.E+06" is 3.2×10 6 means.
[0261]
[0262] As shown in Table 11, in Examples 14 and 15, compared to Comparative Example 4, the number of iPS cells at Day 0 and the area of the upper surface of the cell scaffold per cm 2 It can be seen that a large number of CD56-positive cells were obtained.
[0263] Example 16 (1) Preparation of cell culture substrate A cell culture substrate A1 was obtained in the same manner as in Example 7, except that the structure of the cell scaffold material was changed as shown in the table below.
[0264] Furthermore, rhDLL4 / Fc chimeric protein solution (10 μg / mL, manufactured by Sino Biological Co., Ltd.) was diluted with an equal volume of RetroNectin solution (10 μg / mL, manufactured by Takara Bio Inc.), and 1 mL of the solution was added to each well of a 6-well plate (surface treatment: tissue culture treatment (TC treatment)) and incubated overnight at 4°C. In this way, cell culture substrate B1 was obtained. Similarly, rhDLL4 / Fc chimeric protein solution (10 μg / mL, manufactured by Sino Biological Co., Ltd.) was diluted with an equal volume of RetroNectin solution (10 μg / mL, manufactured by Takara Bio Inc.) and 0.4 mL of the solution was added to each well of a 24-well plate (surface treatment: tissue culture treatment (TC treatment)) and incubated overnight at 4°C. In this way, cell culture substrate B2 was obtained.
[0265] (2) Cell Culture Differentiation induction media A3 to C3 and F2 shown in the table below were prepared.
[0266]
[0267] The obtained cell culture substrate A1 was used, and six wells of the cell culture substrate A1 were seeded with cells at a seeding density of 1.6 × 10 5 The steps from "(2-1) iPS cell maintenance culture" to "(2-2) iPS cell culture (cell aggregate formation step)" were carried out in the same manner as in Example 10, except that the cells were seeded in a 100% iPS cell / well ratio.
[0268] (2-3) Differentiation Induction Step (Step (1), Day 0 to Day 4) 1 mL of medium A3 was added to the cell culture substrate A1, and the cells were incubated at 37°C and CO in a state where the cell masses were adhered to the surface of the cell scaffold. 2 The cells were cultured for 4 days at a concentration of 5%. On the second day (Day 2) after the start of culture in Medium A3, 6 μM SB431542 (Fujifilm Wako Pure Chemical Industries, Ltd.) was added. In this way, a cell population containing mesoderm was obtained.
[0269] (2-4) Differentiation Induction Step (Step (2), Day 4 to Day 7) The medium A3 in the cell culture substrate A1 was removed, and 1 mL of medium B3 was added to the cell culture substrate A1. The cells were cultured at 37°C and CO in a state where a cell population containing mesoderm adhered to the surface of the cell scaffold.2 The cells were cultured at a concentration of 5% for 3 days, thus obtaining a cell population containing hemogenic endothelial cells.
[0270] (2-5) Differentiation Induction Step (Step (3), Day 7 to Day 15) The medium B3 in the cell culture substrate A1 was removed, and 1 mL of medium C3 was added to the cell culture substrate A1. In a state where a cell population containing hemogenic endothelial cells was adhered to the surface of the cell scaffold, the cells were cultured at 37°C and CO 2 The cells were cultured for 8 days at a concentration of 5%. During the culture, the entire liquid in the cell culture substrate A1 was replaced with fresh medium C3 every two days until Day 11, but the medium was not replaced after Day 11. In this way, a cell population containing hematopoietic progenitor cells was obtained.
[0271] (2-6) Differentiation Induction Step (Steps (4B) to (5B), Day 15 to Day 37) Cells in the cell culture substrate A1 were detached and collected using a detachment agent (TrypLE Select, manufactured by Thermo Fisher Scientific) at 37°C for 15 minutes. The collected cells were finely divided by approximately 15 cycles using a 2.5ML 21G syringe with an injection needle (manufactured by Terumo Corporation), and then single cells were collected using a 40μm cell strainer (manufactured by BD Japan). CD34-positive cells were collected from the collected cells using the magnetic bead method with the Easy Sep Human CD34 Positive Selection Kit II (manufactured by Stemcell Technologies). The number of collected CD34-positive cells was measured using a cell counter (TC20, manufactured by BioRad).
[0272] 2.0 × 10 of the collected CD34-positive cells were placed on cell culture substrate B1. 4 CD34-positive cells were seeded on the cell culture substrate B1, 2 mL of medium F2 was added, and the cells were incubated at 37°C and CO 2The cells were cultured for 8 days at a concentration of 5%. On Day 17 and Day 23, the liquid in the cell culture substrate B1 was collected into a tube and centrifuged, the medium F2 was removed, and replaced with an equal amount of fresh medium F2, and the substrate was returned to the original cell culture substrate B1. On Day 30, the liquid in the cell culture substrate B1 was collected into a tube and centrifuged, the medium F2 was removed, and replaced with 400 μL of fresh medium F2, and the cells were then seeded onto a newly prepared cell culture substrate B2. On Day 36, the liquid in the cell culture substrate B2 was collected into a tube and centrifuged, the medium F2 was removed, and replaced with an equal amount of fresh medium F2. On Day 37, all cells in the cell culture substrate B2 were collected by pipetting.
[0273] Example 17 (1) Preparation of cell culture substrate A cell culture substrate A2 was obtained in the same manner as in Example 7, except that the structure of the cell scaffold material was changed as shown in the table below.
[0274] Furthermore, rhDLL4 / Fc chimeric protein solution (10 μg / mL, manufactured by Sino Biological Co., Ltd.) was diluted with an equal volume of RetroNectin solution (10 μg / mL, manufactured by Takara Bio Inc.), and 0.4 mL of the solution was added to each well of a 48-well plate (surface treatment: tissue culture treatment (TC treatment)) and incubated overnight at 4°C. In this way, cell culture substrate B3 was obtained. Similarly, rhDLL4 / Fc chimeric protein solution (10 μg / mL, manufactured by Sino Biological Co., Ltd.) was diluted with an equal volume of RetroNectin solution (10 μg / mL, manufactured by Takara Bio Inc.) and 0.8 mL of the solution was added to each well of a 12-well plate (surface treatment: tissue culture treatment (TC treatment)) and incubated overnight at 4°C. In this way, cell culture substrate B4 was obtained.
[0275] (2) Cell Culture Differentiation induction media A4 to C4 and F3 shown in the table below were prepared.
[0276]
[0277] The obtained cell culture substrate A2 was used, and the seeding density of 1.4 × 10 cells was 1.4 × 10 cells per well of the cell culture substrate A2. 5The steps from "(2-1) iPS cell maintenance culture" to "(2-2) iPS cell culture (cell aggregate formation step)" were carried out in the same manner as in Example 10, except that the cells were seeded in a 100% iPS cell / well ratio.
[0278] (2-3) Differentiation Induction Step (Step (1), Day 0 to Day 2) 1 mL of medium A4 was added to the cell culture substrate A2, and the cells were incubated at 37°C and CO in a state where the cell aggregates were adhered to the surface of the cell scaffold. 2 The cells were cultured for 2 days at a concentration of 5%. In this way, a cell population containing mesoderm was obtained.
[0279] (2-4) Differentiation Induction Step (Step (2), Day 2 to Day 4) Medium A4 was removed from the cell culture substrate A2, and 1 mL of medium B4 was added to the cell culture substrate A2. The cells were incubated at 37°C and CO in a state where a mesoderm-containing cell population was adhered to the surface of the cell scaffold. 2 The cells were cultured at a concentration of 5% for 2 days, thus obtaining a cell population containing hemogenic endothelial cells.
[0280] (2-5) Differentiation Induction Step (Step (3), Day 4 to Day 14) Medium B4 was removed from the cell culture substrate A2, and 1 mL of medium C4 was added to the cell culture substrate A2. The cell culture substrate A2 was then incubated at 37°C and CO in a state where a cell population containing hemogenic endothelial cells was adhered to the surface of the cell scaffold. 2 The cells were cultured for 10 days at a concentration of 5%. During the culture, the liquid in the cell culture substrate A2 was replaced with fresh medium C4 every two days until Day 11, but the medium was not replaced after Day 11. In this way, a cell population containing hematopoietic progenitor cells was obtained.
[0281] (2-6) Differentiation induction step (steps (4B) to (5B), Day 14 to Day 33) Cells floating in the cell culture substrate A2 (cells floating without adhering to the cell scaffold) were collected using a pipette. CD34-positive cells were collected from the collected cells by the magnetic bead method using Easy Sep Human CD34 Positive Selection Kit II (manufactured by Stemcell Technologies). The number of collected CD34-positive cells was measured using a cell counter (manufactured by BioRad "TC20").
[0282] 1.28 × 10 of the collected CD34-positive cells were placed on cell culture substrate B3. 4 CD34-positive cells were seeded on the cell culture substrate B3, 0.5 mL of medium F3 was added, and the cells were incubated at 37°C and CO 2 The cells were cultured for 14 days at a concentration of 5%. On Days 19, 21, 23, and 26, the liquid in the cell culture substrate B3 was collected into a tube and centrifuged, medium F3 was removed, and replaced with an equal amount of fresh medium F3, and the substrate was returned to the original cell culture substrate B3. On Day 28, the liquid in the cell culture substrate B3 was collected into a tube and centrifuged, medium F3 was removed, and replaced with 1 mL of fresh medium F3, and then the substrate was seeded onto a newly prepared cell culture substrate B4. On Day 33, all cells in the cell culture substrate B4 were collected by pipetting.
[0283] Example 18 In the same manner as in Example 17, the steps up to Day 13 of "(2-5) Differentiation induction step (step (3))" were carried out.
[0284] (2-6) Differentiation induction step (steps (4B) to (5B), Day 13 to Day 34) Cells floating in the cell culture substrate A2 (cells floating without adhering to the cell scaffold) were collected using a pipette. The number of collected cells was measured using a cell counter ("TC20" manufactured by BioRad). A portion of the collected cells was sampled and labeled with an anti-CD34 antibody (manufactured by BD Pharmingen), and then measured and analyzed using a flow cytometer ("BD FACSLyric" manufactured by BD) to determine the CD34 positivity rate. The number of collected CD34-positive cells was calculated by multiplying the number of collected cells by the CD34 positivity rate.
[0285] The number of CD34-positive cells was 3.6 × 10 2 The cells recovered from the cell culture substrate A2 were seeded into the cell culture substrate B4 to form 100 cells, and 1 mL of medium F3 was added to the cell culture substrate B4. The cells were then incubated at 37°C and CO 2The cells were cultured for 21 days under conditions of a 5% concentration. On Day 18, the liquid in the cell culture substrate B4 was collected into a tube and centrifuged, medium F3 was removed and replaced with an equal amount of fresh medium F3, and the substrate was returned to the original cell culture substrate B4. On Days 20 and 22, the liquid in the cell culture substrate B4 was collected into a tube and centrifuged, medium F3 was removed and replaced with 1 mL of fresh medium F3, and the cells were then seeded onto a newly prepared cell culture substrate B4. On Days 25, 28, and 32, the liquid in the cell culture substrate B4 was collected into a tube and centrifuged, medium F3 was removed and replaced with an equal amount of fresh medium F3, and the substrate was returned to the original cell culture substrate B4. On Day 35, all cells in the cell culture substrate B4 were collected by pipetting.
[0286] (Evaluation: Examples 16 to 18) (1) Number of recovered cells The number of recovered cells was measured using a cell counter ("TC20" manufactured by BioRad).
[0287] (2) Number of CD3-Positive Cells The collected cells were labeled with FITC-anti-CD3 antibody (manufactured by BD Biosciences), and then measured and analyzed using a flow cytometer (BD Japan, "Lyric") to calculate the number of CD3-positive cells.
[0288] (3) Number of CD3-Positive Cells / Number of iPS Cells The number of CD3-positive cells obtained from one iPS cell (number of CD3-positive cells / number of iPS cells) was calculated using the following formula.
[0289] (Number of CD3-positive cells / Number of iPS cells) = A / B x C / D A: Number of CD3-positive cells (cells) B: Number of seeded CD34-positive cells (cells) C: Number of recovered CD34-positive cells (cells) D: Number of seeded iPS cells (cells)
[0290] The details and results are shown in the table below. In the table below, ".E+0N" means "×10 N ", for example, "3.2.E+06" means 3.2 × 10 6 means.
[0291]
[0292]
[0293] As shown in Tables 14 and 15, it can be seen that CD3-positive cells were obtained in Examples 16 to 18. Furthermore, it can be seen that in Examples 17 and 18, which included the steps of recovering floating cells from the obtained cell population containing hematopoietic progenitor cells and culturing the recovered cells in the presence of a medium containing a differentiation-inducing factor to obtain a cell population containing lymphoid progenitor cells, the number of CD3-positive cells obtained from one iPS cell was increased compared to Example 16.
[0294] REFERENCE SIGNS LIST 1... cell culture substrate 2... substrate 2a... first surface 3... cell scaffold material 3a... upper surface D: diameter (circle equivalent diameter) H: height L: distance between centers of gravity
Claims
1. A method for producing hematopoietic progenitor cells, comprising: a cell cluster formation step of culturing pluripotent stem cells using a cell culture substrate comprising a substrate and a cell scaffold material arranged in a dot pattern on a first surface of the substrate, and forming cell clusters on the surface of the cell scaffold material; and a differentiation induction step of inducing differentiation of the obtained cell clusters into a cell population including hematopoietic progenitor cells.
2. The method for producing hematopoietic progenitor cells described in claim 1, wherein the average equivalent circle diameter of the upper surface of the cell scaffold is 200 μm or more and 3000 μm or less.
3. A method for producing hematopoietic progenitor cells as described in claim 1 or 2, wherein the average distance between the centers of gravity of the upper surface of the cell scaffold material is 0.5 mm or more and 10 mm or less.
4. A method for producing hematopoietic progenitor cells according to any one of claims 1 to 3, wherein the cell scaffolding material comprises a peptide-containing resin having a synthetic resin portion and a peptide portion.
5. The method for producing hematopoietic progenitor cells according to claim 4, wherein the peptide-containing resin has a polyvinyl acetal resin portion and a peptide portion.
6. A method for producing hematopoietic progenitor cells described in any one of claims 1 to 5, wherein the area on the first surface of the substrate where the cell scaffold material is not placed has an area that has been treated to reduce cell adhesion.
7. A method for producing hematopoietic progenitor cells described in any one of claims 1 to 6, wherein the pluripotent stem cells are iPS cells.
8. A method for producing white blood cells, comprising a step of inducing differentiation of a cell population containing hematopoietic progenitor cells obtained by the method for producing hematopoietic progenitor cells described in any one of claims 1 to 7 into a cell population containing monocytes, lymphocytes or granulocytes.
9. A method for producing white blood cells, comprising: a cell cluster formation step of culturing pluripotent stem cells using a cell culture substrate comprising a substrate and a cell scaffold material arranged in a dot pattern on a first surface of the substrate, and forming cell clusters on the surface of the cell scaffold material; and a differentiation induction step of inducing differentiation of the obtained cell clusters into a cell population including monocytes, lymphocytes or granulocytes.
10. The method for producing white blood cells described in claim 9, wherein the average circle equivalent diameter of the upper surface of the cell scaffold material is 200 μm or more and 3000 μm or less.
11. A method for producing white blood cells as described in claim 9 or 10, wherein the average distance between the centers of gravity of the upper surface of the cell scaffolding material is 0.5 mm or more and 10 mm or less.
12. A method for producing leukocytes described in any one of claims 9 to 11, wherein the cell scaffolding material comprises a peptide-containing resin having a synthetic resin portion and a peptide portion.
13. The method for producing leukocytes described in claim 12, wherein the peptide-containing resin has a polyvinyl acetal resin portion and a peptide portion.
14. A method for producing white blood cells described in any one of claims 9 to 13, wherein the area on the first surface of the substrate where the cell scaffold material is not placed has an area that has been treated to reduce cell adhesion.
15. A method for producing white blood cells according to any one of claims 9 to 14, wherein the pluripotent stem cells are iPS cells.
Citation Information
Patent Citations
Methods for inducing differentiation from pluripotent stem cells to ectodermal cells and methods for making such cells
JP2021158960A
Cell structure and production method thereof
JP2021185810A
Derivation of human microglia from pluripotent stem cells
US20160186137A1
Scaffold material for cell culture and cell culture container
WO2021024943A1
Neutrophil progenitor cells and method for producing same
WO2021090594A1
